top of page
Ref 186

References

  1. Altman DG. Better reporting of randomised controlled trials: the CONSORT statement. BMJ. 1996;313(7057):570-1.

  2. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-4.

  3. Summerskill W, Collingridge D, Frankish H. Protocols, probity, and publication. Lancet. 2009;373:992.

  4. Li T, Boutron I, Salman RA-S, Cobo E, Flemyng E, Grimshaw JM, et al. Review and publication of protocol submissions to Trials – what have we learned in 10 years? Trials. 2016;18(1):34.

  5. Hróbjartsson A, Pildal J, Chan A-W, Haahr MT, Altman DG, Gøtzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. Journal of Clinical Epidemiology. 2009;62(9):967-73.

  6. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200-7.

  7. Schulz KF, Altman DG, Moher D, the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.

  8. SPIRIT-CONSORT website. Accessed at: https://www.consort-spirit.org/ on June 25, 2024.

  9. Gryaznov D, Niederhäusern Bv, Speich B, Kasenda B, Ojeda-Ruiz E, Blümle A, et al. Reporting quality of clinical trial protocols: a repeated cross-sectional study about the Adherence to SPIrit Recommendations in Switzerland, CAnada and GErmany (ASPIRE-SCAGE). BMJ Open. 2022;12(5):e053417.

  10. Speich B, Odutayo A, Peckham N, Ooms A, Stokes JR, Saccilotto R, et al. A longitudinal assessment of trial protocols approved by research ethics committees: The Adherance to SPIrit REcommendations in the UK (ASPIRE-UK) study. Trials. 2022;23(1):601.

  11. Tan ZW, Tan AC, Li T, Harris I, Naylor JM, Siebelt M, et al. Has the reporting quality of published randomised controlled trial protocols improved since the SPIRIT statement? A methodological study. BMJ Open. 2020;10(8):e038283.

  12. Blanco D, Donadio MVF, Cadellans-Arróniz A. Enhancing reporting through structure: a before and after study on the effectiveness of SPIRIT-based templates to improve the completeness of reporting of randomized controlled trial protocols. Res Integr Peer Rev. 2024;9(1):6.

  13. Chan A-W, Boutron I, Collins GS, Hopewell S, Moher D, Schulz KF, et al. SPIRIT 2024 Statement: updated guideline for protocols of randomised trials (Unpublished). 2024.

  14. Hopewell S, Chan A-W, Collins GS, Hróbjartsson A, Moher D, Schulz KF, et al. CONSORT 2024 Statement: updated guideline for reporting randomised trials (Unpublished). 2024.

  15. World Health Organization. Guidance for best practices for clinical trials. 2024. Accessed at https://www.who.int/publications/i/item/9789240097711 on September 09, 2024.

  16. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. PLoS Med. 2010;7(2):e1000217.

  17. Hopewell S, Boutron I, Chan AW, Collins GS, de Beyer JA, Hróbjartsson A, et al. An update to SPIRIT and CONSORT reporting guidelines to enhance transparency in randomized trials. Nat Med. 2022;28(9):1740-3.

  18. Nejstgaard CH, Boutron I, Chan AW, Chow R, Hopewell S, Masalkhi M, et al. A scoping review identifies multiple comments suggesting modifications to SPIRIT 2013 and CONSORT 2010. J Clin Epidemiol. 2023;155:48-63.

  19. Tunn R, Boutron I, Chan AW, Collins GS, Hróbjartsson A, Moher D, et al. Methods used to develop the SPIRIT 2024 and CONSORT 2024 Statements. J Clin Epidemiol. 2024:111309.

  20. Østengaard L, Barrientos A, Boutron I, Chan AW, Collins G, Hopewell S, et al. Development of a topic-specific bibliographic database supporting the updates of SPIRIT 2013 and CONSORT 2010. Cochrane Ev Synth. 2024:2:e12057.

  21. Rivera SC, Liu X, Chan A-W, Denniston AK, Calvert MJ. Guidelines for clinical trial protocols for interventions involving artificial intelligence: the SPIRIT-AI Extension. BMJ. 2020;370:m3210.

  22. Butcher NJ, Monsour A, Mew EJ, Chan A-W, Moher D, Mayo-Wilson E, et al. Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension. JAMA. 2022;328(23):2345-56.

  23. Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan A-W, King MT, et al. Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension. JAMA. 2018;319(5):483-94.

  24. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ : British Medical Journal. 2014;348:g1687.

  25. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. Bmj. 2013;346:e7586.

  26. Barnes C, Boutron I, Giraudeau B, Porcher R, Altman DG, Ravaud P. Impact of an online writing aid tool for writing a randomized trial report: the COBWEB (Consort-based WEB tool) randomized controlled trial. BMC Med. 2015;13:221.

  27. Engdahl J, Straat K, Isaksson E, Rooth E, Svennberg E, Norrving B, et al. Multicentre, national, investigator-initiated, randomised, parallel-group, register-based superiority trial to compare extended ECG monitoring versus standard ECG monitoring in elderly patients with ischaemic stroke or transient ischaemic attack and the effect on stroke, death and intracerebral bleeding: the AF SPICE protocol. BMJ Open. 2023;13(11):e073470.

  28. Dickersin K, Manheimer E, Wieland S, Robinson KA, Lefebvre C, McDonald S. Development of the Cochrane Collaboration's CENTRAL Register of controlled clinical trials. Eval Health Prof. 2002;25(1):38-64.

  29. Australian and New Zealand Clinical Trials Registry [Internet]: Sydney (NSW): NHMRC Clinical Trials Centre, University of Sydney (Australia); 2023 - Identifier ACTRN12624000133538. Encapsulated faecal microbiome transfer versus oral vancomycin treatment for sustained cure of recurrent or refractory Clostridioides difficile infection. Accessed at https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386924 on October 13, 2024.

  30. World Health Organization. WHO Trial Registration Data Set (Version 1.3.1). Available at: https://www.who.int/clinical-trials-registry-platform/network/who-data-set [Accessed 12 March 2024].

  31. European Commission. Clinical trials - Regulation EU No 536/2014. 2022 Available at: https://health.ec.europa.eu/medicinal-products/clinical-trials/clinical-trials-regulation-eu-no-5362014_en [Accessed 17 May 2024].

  32. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, et al. Clinical trial registration. Bmj. 2007;334(7605):1177-8.

  33. National Institutes of Health Department of Health and Human Services. Final Rule 81 FR 64982: Clinical Trials Registration and Results Information Submission. Available at https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission [accessed 12 March 2024]. 2016. p. 64982-5157.

  34. Hill KD, Kannankeril PJ, Jacobs JP, Baldwin HS, Jacobs ML, O’Brien SM, et al. Methylprednisolone for Heart Surgery in Infants — A Randomized, Controlled Trial. New England Journal of Medicine. 2022;387(23):2138-49.

  35. Getz KA, Stergiopoulos S, Short M, Surgeon L, Krauss R, Pretorius S, et al. The Impact of Protocol Amendments on Clinical Trial Performance and Cost. Therapeutic Innovation & Regulatory Science. 2016;50(4):436-41.

  36. Getz K, Smith Z, Botto E, Murphy E, Dauchy A. New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance. Therapeutic Innovation & Regulatory Science. 2024;58:539–48.

  37. Hemingway-Foday J, Tita A, Chomba E, Mwenechanya M, Mweemba T, Nolen T, et al. Prevention of maternal and neonatal death/infections with a single oral dose of azithromycin in women in labour in low-income and middle-income countries (A-PLUS): a study protocol for a multinational, randomised placebo-controlled clinical trial. BMJ Open. 2023;13(8):e068487.

  38. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Constraints on publication rights in industry-initiated clinical trials. JAMA. 2006;295(14):1645-6.

  39. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Ghost authorship in industry-initiated randomised trials. PLoS Med. 2007;4(1):e19.

  40. Schroter S, Montagni I, Loder E, Eikermann M, Schäffner E, Kurth T. Awareness, usage and perceptions of authorship guidelines: an international survey of biomedical authors. BMJ Open. 2020;10(9):e036899.

  41. Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, et al. Honorary and ghost authorship in reports of randomised clinical trials in oncology. Eur J Cancer. 2016;66:1-8.

  42. JAMA Network. JAMA Instructions for Authors: authorship and disclosures. Last updated 6 March 2024. Available at: https://jamanetwork.com/journals/jama/pages/instructions-for-authors#SecAuthorshipandDisclosures [Accessed 11 March 2024].

  43. International Committee of Medical Journal Editors. Defining the Role of Authors and Contributors. Available at: https://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html [Accessed 08 May 2024].

  44. Com-COV3 Protocol Date & Version No: V11.0 13 Dec 2022. https://comcovstudy.org.uk/sitefiles/com-cov3-protocol-v11.0-13-dec-2023-unsigned.pdf (Accessed 13.03.2023).

  45. World Health Organization. Standards and operational guidance for ethics review of health-related research with human participants. 2011 Available at: https://www.who.int/publications/i/item/9789241502948 [Accessed 13 March 2024].

  46. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). Step 4 version dated 9 November 2016. Available at: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf. Accessed 15 Nov 2023.

  47. Sakzewski L, Reedman SE, Elliott C, Ziviani J, Novak I, Trost S, et al. Participate CP 2: optimising participation in physically active leisure for children with cerebral palsy – protocol for a phase III randomised controlled trial. BMJ Open. 2023;13(10):e075570.

  48. Mello MM, Clarridge BR, Studdert DM. Academic medical centers' standards for clinical-trial agreements with industry. N Engl J Med. 2005;352(21):2202-10.

  49. Rochon PA, Sekeres M, Hoey J, Lexchin J, Ferris LE, Moher D, et al. Investigator experiences with financial conflicts of interest in clinical trials. Trials. 2011;12:9.

  50. Paludan-Muller AS, Ogden MC, Marquardsen M, Jorgensen KJ, Gotzsche PC. Are investigators' access to trial data and rights to publish restricted and are potential trial participants informed about this? A comparison of trial protocols and informed consent materials. BMC Med Ethics. 2021;22(1):115.

  51. Kasenda B, von Elm E, You JJ, Blümle A, Tomonaga Y, Saccilotto R, et al. Agreements between Industry and Academia on Publication Rights: A Retrospective Study of Protocols and Publications of Randomized Clinical Trials. PLOS Medicine. 2016;13(6):e1002046.

  52. Nejstgaard CH, Laursen DRT, Lundh A, Hróbjartsson A. Commercial funding and estimated intervention effects in randomized clinical trials: Systematic review of meta-epidemiological studies. Res Synth Methods. 2023;14(2):144-55.

  53. Bais T, Meijer E, Kramers BJ, Vart P, Vervloet M, Salih M, et al. HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial. Trials. 2024;25(1):120.

  54. DAMOCLES Study Group NHTAP. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365(9460):711-22.

  55. Harman NL, Conroy EJ, Lewis SC, Murray G, Norrie J, Sydes MR, et al. Exploring the role and function of trial steering committees: results of an expert panel meeting. Trials. 2015;16(1):597.

  56. Raeside R, Spielman K, Maguire S, Mihrshahi S, Steinbeck K, Kang M, et al. A healthy lifestyle text message intervention for adolescents: protocol for the Health4Me randomized controlled trial. BMC Public Health. 2022;22(1):1805.

  57. UNESCO. UNESCO Recommendation on Open Science. 2021 Available at: https://unesdoc.unesco.org/ark:/48223/pf0000379949 [Accessed 09 Nov 2023].

  58. Sim I, Chan AW, Gulmezoglu AM, Evans T, Pang T. Clinical trial registration: transparency is the watchword. Lancet. 2006;367(9523):1631-3.

  59. Dickersin K, Rennie D. Registering clinical trials. JAMA. 2003;290(4):516-23.

  60. Krleža-Jeric K, Chan A-W, Dickersin K, Sim I, Grimshaw J, Gluud C, et al. Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement (part 1). BMJ. 2005;330:956-8.

  61. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. JAMA. 2004;292(11):1363-4.

  62. Zarin DA, Tse T, Williams RJ, Rajakannan T. Update on Trial Registration 11 Years after the ICMJE Policy Was Established. N Engl J Med. 2017;376(4):383-91.

  63. Chan A-W, Pello A, Kitchen J, Axentiev A, Virtanen JI, Liu A, et al. Association of Trial Registration With Reporting of Primary Outcomes in Protocols and Publications. JAMA. 2017;318(17):1709-11.

  64. TARG Meta-Research Group Collaborators. Estimating the prevalence of discrepancies between study registrations and publications: a systematic review and meta-analyses. BMJ Open. 2023;13(10):e076264.

  65. Sender D, Clark J, Hoffmann TC. Analysis of articles directly related to randomized trials finds poor protocol availability and inconsistent linking of articles. J Clin Epidemiol. 2020;124:69-74.

  66. United States Congress. Food and Drug Administration Amendments Act of 2007, Title VIII, Section 801. Expanded clinical trial registry data bank. 2007 Available at: https://www.govtrack.us/congress/bills/110/hr3580/text [Accessed 12 May 2024].

  67. SPIRIT Electronic Protocol Tool and Resource (SEPTRE). Accessed at: https://spiritprotocol.com on June 19, 2024.

  68. Barticevic NA, Poblete F, Zuzulich SM, Rodriguez V, Bradshaw L. Brief motivational therapy versus enhanced usual care for alcohol use disorders in primary care in Chile: study protocol for an exploratory randomized trial. Trials. 2020;21(1):692.

  69. Walsh TS, Aitken LM, McKenzie CA, Boyd J, Macdonald A, Giddings A, et al. Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK. BMJ Open. 2023;13(12):e078645.

  70. International Conference on Harmonisation (ICH). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Statistical Principles for Clinical Trials E9. London, England: European Medicines Agency. 1998.

  71. Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Doré C, et al. Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA. 2017;318(23):2337-43.

  72. Hemming K, Kearney A, Gamble C, Li T, Jüni P, Chan A-W, et al. Prospective reporting of statistical analysis plans for randomised controlled trials. Trials. 2020;21(1):898.

  73. Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, et al. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. JAMA. 2021;326(3):257-65.

  74. Chan AW. Bias, spin, and misreporting: Time for full access to trial protocols and results. PLoS Med. 2008;5(11):e230.

  75. Schönenberger CM, Griessbach A, Taji Heravi A, Gryaznov D, Gloy VL, Lohner S, et al. A meta-research study of randomized controlled trials found infrequent and delayed availability of protocols. Journal of Clinical Epidemiology. 2022;149:45-52.

  76. Campbell D, McDonald C, Cro S, Jairath V, Kahan BC. Access to unpublished protocols and statistical analysis plans of randomised trials. Trials. 2022;23(1):674.

  77. Spence O, Hong K, Onwuchekwa Uba R, Doshi P. Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis. Clin Trials. 2020;17(1):99-105.

  78. Chan A-W, Hróbjartsson A. Promoting public access to clinical trial protocols: challenges and recommendations. Trials. 2018;19(1):116.

  79. Chan AW. Out of sight but not out of mind: how to search for unpublished clinical trial evidence. BMJ. 2011;344:d8013.

  80. Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ. 2012;344:d8141.

  81. Goldacre B, Drysdale H, Dale A, Milosevic I, Slade E, Hartley P, et al. COMPare: a prospective cohort study correcting and monitoring 58 misreported trials in real time. Trials. 2019;20(1):118.

  82. Goldacre B, Drysdale H, Marston C, Mahtani KR, Dale A, Milosevic I, et al. COMPare: Qualitative analysis of researchers’ responses to critical correspondence on a cohort of 58 misreported trials. Trials. 2019;20(1):124.

  83. Taichman DB, Sahni P, Pinborg A, Peiperl L, Laine C, James A, et al. Data sharing statements for clinical trials. BMJ. 2017;357:j2372.

  84. Mangla M, Bedair H, Chang Y, Daggett S, Dwyer MK, Freiberg AA, et al. Protocol for a randomised trial evaluating the comparative effectiveness of strategies to promote shared decision making for hip and knee osteoarthritis (DECIDE-OA study). BMJ Open. 2019;9(2):e024906.

  85. Djimde M, Tshiongo JK, Muhindo HM, Tinto H, Sevene E, Traore M, et al. Efficacy and safety of pyronaridine-artesunate (PYRAMAX) for the treatment of P. falciparum uncomplicated malaria in African pregnant women (PYRAPREG): study protocol for a phase 3, non-inferiority, randomised open-label clinical trial. BMJ Open. 2023;13(10):e065295.

  86. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. Jama. 2015;313(16):1657-65.

  87. Piwowar HA, Day RS, Fridsma DB. Sharing Detailed Research Data Is Associated with Increased Citation Rate. PLOS ONE. 2007;2(3):e308.

  88. Colavizza G, Hrynaszkiewicz I, Staden I, Whitaker K, McGillivray B. The citation advantage of linking publications to research data. PLOS ONE. 2020;15(4):e0230416.

  89. Johnson AL, Anderson JM, Bouvette M, Pinero I, Rauh S, Johnson B, et al. Clinical trial data-sharing policies among journals, funding agencies, foundations, and other professional organizations: a scoping review. J Clin Epidemiol. 2023;154:42-55.

  90. Cheah PY, Piasecki J. Data Access Committees. BMC Medical Ethics. 2020;21(1):12.

  91. Loder E, Macdonald H, Bloom T, Abbasi K. Mandatory data and code sharing for research published by The BMJ. Bmj. 2024;384:q324.

  92. Bloom T, Ganley E, Winker M. Data Access for the Open Access Literature: PLOS's Data Policy. PLoS medicine. 2014;11(2):e1001607.

  93. Naudet F, Sakarovitch C, Janiaud P, Cristea I, Fanelli D, Moher D, et al. Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS Medicine. BMJ. 2018;360:k400.

  94. Bergeat D, Lombard N, Gasmi A, Le Floch B, Naudet F. Data Sharing and Reanalyses Among Randomized Clinical Trials Published in Surgical Journals Before and After Adoption of a Data Availability and Reproducibility Policy. JAMA Network Open. 2022;5(6):e2215209-e.

  95. Rowhani-Farid A, Grewal M, Solar S, Eghrari AO, Zhang AD, Gross CP, et al. Clinical trial data sharing: a cross-sectional study of outcomes associated with two U.S. National Institutes of Health models. Scientific Data. 2023;10(1):529.

  96. Esmail LC, Kapp P, Assi R, Wood J, Regan G, Ravaud P, et al. Sharing of Individual Patient-Level Data by Trialists of Randomized Clinical Trials of Pharmacological Treatments for COVID-19. JAMA. 2023;329(19):1695-7.

  97. Ohmann C, Moher D, Siebert M, Motschall E, Naudet F. Status, use and impact of sharing individual participant data from clinical trials: a scoping review. BMJ Open. 2021;11(8):e049228.

  98. World Medical Association. World Medical Association statement on conflicts of interest. Adopted by the 60 WMA General Assembly, New Delhi, India, October 2009 and editorially revised by the 201st WMA Council Session, Moscow, Russia, October 2015. www.wma.net/policies-post/wma-statement-on-conflict-of-interest. Accessed 19.10.2023.

  99. Lundh A, Krogsbøll LT, Gøtzsche PC. Access to data in industry-sponsored trials. Lancet. 2011;378(9808):1995-6.

  100. Banzi R, Canham S, Kuchinke W, Krleza-Jeric K, Demotes-Mainard J, Ohmann C. Evaluation of repositories for sharing individual-participant data from clinical studies. Trials. 2019;20(1):169.

  101. Schimpf MO, Smith AR, Miller JM. Fluids affecting bladder urgency and lower urinary symptoms (FABULUS): methods and protocol for a randomized controlled trial. International Urogynecology Journal. 2020;31(5):1033-40.

  102. Speich B, von Niederhäusern B, Schur N, Hemkens LG, Fürst T, Bhatnagar N, et al. Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data. J Clin Epidemiol. 2018;96:1-11.

  103. Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost? Nat Rev Drug Discov. 2017;16(6):381-2.

  104. Raftery J, Young A, Stanton L, Milne R, Cook A, Turner D, et al. Clinical trial metadata: defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme. Health Technol Assess. 2015;19(11):1-138.

  105. Rasmussen K, Bero L, Redberg R, Gøtzsche PC, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ. 2018;363:k3654.

  106. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2017;2(2):Mr000033.

  107. Østengaard L, Lundh A, Tjørnhøj-Thomsen T, Abdi S, Gelle MHA, Stewart LA, et al. Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study. BMJ. 2020;371:m3764.

  108. Wagner E, Strube W, Görlitz T, Aksar A, Bauer I, Campana M, et al. Effects of Early Clozapine Treatment on Remission Rates in Acute Schizophrenia (The EARLY Trial): Protocol of a Randomized-Controlled Multicentric Trial. Pharmacopsychiatry. 2023;56(5):169-81.

  109. IOM (Institute of Medicine). Conflict of interest in medical research, education, and practice. Washington, DC: The National Academies Press; 2009.

  110. Ahn R, Woodbridge A, Abraham A, Saba S, Korenstein D, Madden E, et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. BMJ. 2017;356:i6770.

  111. DeSilva M, Vu CN, Bonawitz R, Hai LT, Van Lam N, Yen LT, et al. The Supporting Adolescent Adherence in Vietnam (SAAV) study: study protocol for a randomized controlled trial assessing an mHealth approach to improving adherence for adolescents living with HIV in Vietnam. Trials. 2019;20(1):150.

  112. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, et al. Increasing value and reducing waste: addressing inaccessible research. Lancet. 2014;383(9913):257-66.

  113. Speich B, Gryaznov D, Busse JW, Gloy VL, Lohner S, Klatte K, et al. Nonregistration, discontinuation, and nonpublication of randomized trials: A repeated metaresearch analysis. PLoS Med. 2022;19(4):e1003980.

  114. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14:iii-193.

  115. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database of Systematic Reviews. 2009;1:MR000006.

  116. Dwan K, Gamble C, Williamson PR, Kirkham JJ. Systematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated review. PLoS One. 2013;8(7):e66844.

  117. McGauran N, Wieseler B, Kreis J, Schuler YB, Kolsch H, Kaiser T. Reporting bias in medical research - a narrative review. Trials. 2010;11:37.

  118. Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012;344:d7202.

  119. Emerson GB, Warme WJ, Wolf FM, Heckman JD, Brand RA, Leopold SS. Testing for the presence of positive-outcome bias in peer review: a randomized controlled trial. Arch Intern Med. 2010;170(21):1934-9.

  120. Olson CM, Rennie D, Cook D, Dickersin K, Flanagin A, Hogan JW, et al. Publication bias in editorial decision making. JAMA. 2002;287(21):2825-8.

  121. Zarin DA, Tse T, Williams RJ, Carr S. Trial Reporting in ClinicalTrials.gov — The Final Rule. New England Journal of Medicine. 2016;375(20):1998-2004.

  122. DeVito NJ, Morley J, Smith JA, Drysdale H, Goldacre B, Heneghan C. Availability of results of clinical trials registered on EU Clinical Trials Register: cross sectional audit study. BMJ Medicine. 2024;3(1):e000738.

  123. Chan A-W, Karam G, Pymento J, Askie LM, da Silva LR, Aymé S, et al. Reporting summary results in clinical trial registries: updated guidance from the World Health Organization. Lancet Global Health 2025 (in press).

  124. Alayche M, Cobey KD, Ng JY, Ardern CL, Khan KM, Chan A-W, et al. Evaluating prospective study registration and result reporting of trials conducted in Canada from 2009 to 2019. FACETS. 2023;8:1-10.

  125. Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, et al. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ. 2016;352:i637.

  126. Nelson JT, Tse T, Puplampu-Dove Y, Golfinopoulos E, Zarin DA. Comparison of Availability of Trial Results in ClinicalTrials.gov and PubMed by Data Source and Funder Type. Jama. 2023;329(16):1404-6.

  127. Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med. 2013;10(12):e1001566.

  128. Sherpa Romeo. Available at: https://www.sherpa.ac.uk/romeo/ [Accessed 08 Nov 2023].

  129. ASAPbio. Preprint resource centre. Available at: https://asapbio.org/preprint-info [Accessed 08 Nov 2023].

  130. Kirkham JJ, Penfold NC, Murphy F, Boutron I, Ioannidis JP, Polka J, et al. Systematic examination of preprint platforms for use in the medical and biomedical sciences setting. BMJ Open. 2020;10(12):e041849.

  131. Massey DS, Opare MA, Wallach JD, Ross JS, Krumholz HM. Assessment of Preprint Policies of Top-Ranked Clinical Journals. JAMA Netw Open. 2020;3(7):e2011127.

  132. Zeraatkar D, Pitre T, Leung G, Cusano E, Agarwal A, Khalid F, et al. Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. BMJ Medicine. 2022;1(1):e000309.

  133. Davidson M, Evrenoglou T, Graña C, Chaimani A, Boutron I. No evidence of important difference in summary treatment effects between COVID-19 preprints and peer-reviewed publications: a meta-epidemiological study. J Clin Epidemiol. 2023;162:90-7.

  134. Davidson M, Evrenoglou T, Graña C, Chaimani A, Boutron I. Comparison of effect estimates between preprints and peer-reviewed journal articles of COVID-19 trials. BMC Med Res Methodol. 2024;24(1):9.

  135. Munafo MR, Nosek BA, Bishop DVM, Button KS, Chambers CD, du Sert NP, et al. A manifesto for reproducible science. Nat Hum Behav. 2017;1(1):0021.

  136. Sgro GM, Maurer M, Nguyen B, Siegel JE. Return of aggregate results to study participants: Facilitators, barriers, and recommendations. Contemp Clin Trials Commun. 2023;33:101136.

  137. Bruhn H, Campbell M, Entwistle V, Humphreys R, Jayacodi S, Knapp P, et al. What, how, when and who of trial results summaries for trial participants: stakeholder-informed guidance from the RECAP project. BMJ Open. 2022;12(3):e057019.

  138. Choi S, Jerath A, Jones P, Avramescu S, Djaiani G, Syed S, et al. Cognitive Outcomes after DEXmedetomidine sedation in cardiac surgery: CODEX randomised controlled trial protocol. BMJ Open. 2021;11(4):e046851.

  139. Turgeon AF, Fergusson DA, Clayton L, Patton M-P, Zarychanski R, English S, et al. Haemoglobin transfusion threshold in traumatic brain injury optimisation (HEMOTION): a multicentre, randomised, clinical trial protocol. BMJ Open. 2022;12(10):e067117.

  140. Dobra R, Wilson G, Matthews J, Boeri M, Elborn S, Kee F, et al. A systematic review to identify and collate factors influencing patient journeys through clinical trials. JRSM Open. 2023;14(6):20542704231166621.

  141. Clarke M, Hopewell S, Chalmers I. Clinical trials should begin and end with systematic reviews of relevant evidence: 12 years and waiting. Lancet. 2010;376:20-1.

  142. Abraham I, Calamia M, MacDonald K. Should a Systematic Review Be Required in a Clinical Trial Report? Perhaps, But Not Yet. JAMA Network Open. 2023;6(3):e234226-e.

  143. Jones AP, Conroy E, Williamson PR, Clarke M, Gamble C. The use of systematic reviews in the planning, design and conduct of randomised trials: a retrospective cohort of NIHR HTA funded trials. BMC Medical Research Methodology. 2013;13(1):50.

  144. Clarke M, Brice A, Chalmers I. Accumulating Research: A Systematic Account of How Cumulative Meta-Analyses Would Have Provided Knowledge, Improved Health, Reduced Harm and Saved Resources. PLOS ONE. 2014;9(7):e102670.

  145. Goudie AC, Sutton AJ, Jones DR, Donald A. Empirical assessment suggests that existing evidence could be used more fully in designing randomized controlled trials. J Clin Epidemiol. 2010;63(9):983-91.

  146. Canadian Institutes of Health Research. RCT evaluation criteria and headings. 2024. [Cited May 12, 2024]. Available from: http://www.cihr.ca/e/39187.html.

  147. British Heart Foundation. Clinical Study Grant full application guidance. Available at: https://www.bhf.org.uk/for-professionals/information-for-researchers/what-we-fund/clinical-study/full-clinical-study-grant-application-guidance [Accessed 12 Sept 2023].

  148. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. The Lancet. 2014;383(9912):156-65.

  149. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364:2021-9.

  150. Puhan MA, Vollenweider D, Steurer J, Bossuyt PM, ter Riet G. Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review. BMC Med. 2008;6:28.

  151. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials. 2005;2(3):218-29.

  152. Pandis N, Fleming PS, Koletsi D, Hopewell S. The citation of relevant systematic reviews and randomised trials in published reports of trial protocols. Trials. 2016;17(1):581.

  153. Sheng J, Feldhake E, Zarin DA, Kimmelman J. Completeness of clinical evidence citation in trial protocols: A cross-sectional analysis. Med. 2022;3(5):335-43.e6.

  154. Paludan-Müller AS, Ogden MC, Marquardsen M, Vive J, Jørgensen KJ, Gøtzsche PC. Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols. BMJ Open. 2019;9(11):e026661.

  155. Chaccour C, Ruiz-Castillo P, Richardson M-A, Moncunill G, Casellas A, Carmona-Torre F, et al. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial. Trials. 2020;21(1):498.

  156. Dawson L, Zarin DA, Emanuel EJ, Friedman LM, Chaudhari B, Goodman SN. Considering usual medical care in clinical trial design. PLoS Med. 2009;6(9):e1000111.

  157. Van Luijn JCF, Van Loenen AC, Gribnau FWJ, Leufkens HGM. Choice of comparator in active control trials of new drugs. Ann Pharmacother. 2008;42(11):1605-12.

  158. Johansen HK, Gotzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA. 1999;282(18):1752-9.

  159. Estellat C, Tubach F, Seror R, Alfaiate T, Hajage D, De Rycke Y, et al. Control treatments in biologics trials of rheumatoid arthritis were often not deemed acceptable in the context of care. J Clin Epidemiol. 2016;69:235-44.

  160. Tugwell P, Tovey D. In 2021 When Is It Unethical to Use a Placebo in a Clinical Trial? J Clin Epidemiol. 2021;133:A5-A6.

  161. Howick J, Hoffmann T. How placebo characteristics can influence estimates of intervention effects in trials. Cmaj. 2018;190(30):E908-e11.

  162. Beard DJ, Campbell MK, Blazeby JM, Carr AJ, Weijer C, Cuthbertson BH, et al. Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines). Lancet. 2020;395(10226):828-38.

  163. Crocombe D, Ahmed N, Balakrishnan I, Bordea E, Chau M, China L, et al. ASEPTIC: primary antibiotic prophylaxis using co-trimoxazole to prevent SpontanEous bacterial PeritoniTIs in Cirrhosis-study protocol for an interventional randomised controlled trial. Trials. 2022;23(1):812.

  164. Ware J, Allen JM, Boughton CK, Wilinska ME, Hartnell S, Thankamony A, et al. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. New England Journal of Medicine. 2022;386(3):209-19.

  165. Agency for Healthcare Research and Quality. Using the PICOTS Framework to Strengthen Evidence Gathered in Clinical Trials—Guidance from the AHRQ’s Evidence-based Practice Centers Program. Available at: https://www.fda.gov/media/109448/download [Accessed 13 March 2024].

  166. Lineberry N, Berlin JA, Mansi B, Glasser S, Berkwits M, Klem C, et al. Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry/journal editor perspective. BMJ. 2016;355:i5078.

  167. Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG, CONSORT Group ft. Reporting of Noninferiority and Equivalence Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2012;308(24):2594-604.

  168. Park JJH, Harari O, Dron L, Lester RT, Thorlund K, Mills EJ. An overview of platform trials with a checklist for clinical readers. J Clin Epidemiol. 2020;125:1-8.

  169. Hazim A, Prasad V. A pooled analysis of published, basket trials in cancer medicine. Eur J Cancer. 2018;101:244-50.

  170. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015;350:h2147.

  171. Fleming TR. Clinical trials: discerning hype from substance. Ann Intern Med. 2010;153:400.

  172. Lynggaard H, Bell J, Losch C, Besseghir A, Rantell K, Schoder V, et al. Principles and recommendations for incorporating estimands into clinical study protocol templates. Trials. 2022;23(1):685.

  173. Cro S, Kahan BC, Rehal S, Ster AC, Carpenter JR, White IR, et al. Evaluating how clear the questions being investigated in randomised trials are: systematic review of estimands. BMJ. 2022;378:e070146.

  174. Kahan BC, Hindley J, Edwards M, Cro S, Morris TP. The estimands framework: a primer on the ICH E9(R1) addendum. BMJ. 2024;384:e076316.

  175. European Medicines Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf. 2020.

  176. Homer V, Yap C, Bond S, Holmes J, Stocken D, Walker K, et al. Early phase clinical trials extension to guidelines for the content of statistical analysis plans. BMJ. 2022;376:e068177.

  177. Kahan BC, Hall SS, Beller EM, Birchenall M, Chan A-W, Elbourne D, et al. Reporting of Factorial Randomized Trials: Extension of the CONSORT 2010 Statement. JAMA. 2023;330(21):2106-14.

  178. Kahan BC, Hall SS, Beller EM, Birchenall M, Elbourne D, Juszczak E, et al. Consensus Statement for Protocols of Factorial Randomized Trials: Extension of the SPIRIT 2013 Statement. JAMA Network Open. 2023;6(12):e2346121-e.

  179. Radavelli-Bagatini S, Bondonno CP, Sim M, Blekkenhorst LC, Anokye R, Connolly E, et al. Modification of diet, exercise and lifestyle (MODEL) study: a randomised controlled trial protocol. BMJ Open. 2020;10(11):e036366.

  180. NIHR. Briefing notes for researchers - public involvement in NHS, health and social care research. Version 1.0 - April 2021. Available at: https://www.nihr.ac.uk/documents/briefing-notes-for-researchers-public-involvement-in-nhs-health-and-social-care-research/27371 [Accessed 11 Sept 2023].

  181. Laura P. Forsythe KLC, Victoria Szydlowski, Lauren Fayish, Laurie Davidson, David H. Hickam, Courtney Hall, Geeta Bhat, Denese Neu, Lisa Stewart, Maggie Jalowsky, Naomi Aronson, and Chinenye Ursla Anyanwu. Patient Engagement In Research: Early Findings From The Patient-Centered Outcomes Research Institute. Health Affairs. 2019;38(3):359-67.

  182. Vanderhout S, Nicholls S, Monfaredi Z, Hampel C, Ashdown L, Bilodeau M, et al. Facilitating and supporting the engagement of patients, families and caregivers in research: the “Ottawa model” for patient engagement in research. Research Involvement and Engagement. 2022;8(1):25.

  183. NHMRC. Guidelines for guidelines: consumer involvement. Available at: https://www.nhmrc.gov.au/guidelinesforguidelines/plan/consumer-involvement (updated 23/11/2018) [Accessed 12 May 2024].

  184. Consumers Health Forum of Australia. Statement on Consumer and Community involvement in Health and Medical Research. 2016 Available at: https://www.nhmrc.gov.au/sites/default/files/documents/reports/consumer-community-involvement.pdf [Accessed 09 Sept 2023].

  185. Canadian Institutes of Health Research. Strategy for Patient-Oriented Research: Patient Engagement Framework. Available at: https://cihr-irsc.gc.ca/e/documents/spor_framework-en.pdf [Accessed 09 Sept 2023].

  186. Husson M, Dechartres A, Ramdjee B, Diverres M, Zejli T, L'Hénaff M, et al. Patient and public involvement is suboptimal in randomized controlled trials addressing a chronic condition. Journal of Clinical Epidemiology. 2023;160:71-82.

  187. Staley K. Exploring Impact: Public involvement in NHS, public health and social care research. 2009 Available at: https://www.invo.org.uk/wp-content/uploads/2011/11/Involve_Exploring_Impactfinal28.10.09.pdf [Accessed 12 May 2024].

  188.  INVOLVE. Public involvement in clinical trials: Supplement to the briefing notes for researchers. 2012 Available at: https://www.invo.org.uk/wp-content/uploads/2012/04/INVOLVEpublicinvolvementinclinicaltrialsBriefingnotes2012.pdf [Accessed 09 Sept 2023].

  189. Price A, Albarqouni L, Kirkpatrick J, Clarke M, Liew SM, Roberts N, et al. Patient and public involvement in the design of clinical trials: An overview of systematic reviews. Journal of Evaluation in Clinical Practice. 2018;24(1):240-53.

  190. National Academies of Sciences E, Medicine. Integrating Clinical Research into Epidemic Response: The Ebola Experience. Keusch G, McAdam K, Cuff PA, Mancher M, Busta ER, editors. Washington, DC: The National Academies Press; 2017. 342 p.

  191. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research. BMJ. 2017;358:j3453.

  192. Middelkoop MA, Huirne JAF, van der Weide MCJ, Bosmans JE, Hehenkamp WJK. A multi-centre, randomized, non-inferiority trial to compare ulipristal with standard surgical treatment in women with symptomatic uterine fibroids: Protocol of the MYOMEX-2 trial. Eur J Obstet Gynecol Reprod Biol. 2021;256:63-9.

  193. Ghosn L, Boutron I, Ravaud P. Consolidated Standards of Reporting Trials (CONSORT) extensions covered most types of randomized controlled trials, but the potential workload for authors was high. J Clin Epidemiol. 2019;113:168-75.

  194. Juszczak E, Altman DG, Hopewell S, Schulz K. Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement. Jama. 2019;321(16):1610-20.

  195. Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;366:l4378.

  196. Campbell MK, Piaggio G, Elbourne DR, Altman DG. Consort 2010 statement: extension to cluster randomised trials. BMJ : British Medical Journal. 2012;345:e5661.

  197. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJW. Reporting of noninferiority and equivalence randomized trials: An extension of the CONSORT statement. JAMA. 2006;295:1152-60.

  198. Fleming TR, Odem-Davis K, Rothmann MD, Li SY. Some essential considerations in the design and conduct of non-inferiority trials. Clin Trials. 2011;8(4):432-9.

  199. Krysan DJ, Kemper AR. Claims of equivalence in randomized controlled trials of the treatment of bacterial meningitis in children. Pediatric Infectious Disease Journal. 2002;21(8):753-8.

  200. Tinmouth JM, Steele LS, Tomlinson G, Glazier GH. Are claims of equivalency in digestive diseases trials supported by the evidence. Gastroenterol. 2004;126:1700-10.

201. Chan AW, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in

randomised trials: comparison of publications with protocols. BMJ. 2008;337:a2299.

202. Kadia BM, Khouma M, Sow D, Faye B, Ramsteijn AS, Calvo-Urbano B, et al. Improving gut health and growth in early life: a protocol for an

individually randomised, two-arm, open-label, controlled trial of a synbiotic in infants in Kaffrine District, Senegal. BMJ Paediatrics Open. 2024;8(Suppl 1):e001629.

203. Hayes K, Janssen P, Payne BA, Jevitt C, Johnston W, Johnson P, et al. Oral Probiotic Supplementation in Pregnancy to Reduce Group B

Streptococcus Colonisation (OPSiP trial): study protocol for a double-blind parallel group randomised placebo trial. BMJ Open. 2024;14(2):e076455.

204. Rothwell PM. Commentary: External validity of results of randomized trials: disentangling a complex concept. Int J Epidemiol.

2010;39(1):94-6.

205. Beckwée D, Nijs J, Bierma-Zeinstra SMA, Leemans L, Leysen L, Puts S, et al. Exercise therapy for knee osteoarthritis pain: how does it

work? A study protocol for a randomised controlled trial. BMJ Open. 2024;14(1):e074258.

206. Prescott RJ, Counsell CE, Gillespie WJ, Grant AM, Russell IT, Kiauka S, et al. Factors that limit the quality, number and progress of

randomised controlled trials. Health Technol Assess. 1999;3(20):1-143.

207. Rendell JM, Merritt RK, Geddes JR. Incentives and disincentives to participation by clinicians in randomised controlled trials. Cochrane

Database of Systematic Reviews. 2007;2:MR000021.

208. Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, et al. Barriers to recruiting underrepresented populations to cancer clinical

trials: a systematic review. Cancer. 2008;112(2):228-42.

209. Elkins JS, Khatabi T, Fung L, Rootenberg J, Johnston SC. Recruiting subjects for acute stroke trials: a meta-analysis. Stroke. 2006;37(1):123-8.

210. Lemieux J, Goodwin PJ, Pritchard KI, Gelmon KA, Bordeleau LJ, Duchesne T, et al. Identification of cancer care and protocol characteristics

associated with recruitment in breast cancer clinical trials. Journal of Clinical Oncology. 2008;26:4458-65.

211. Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol.

2005;23(13):3112-24.

212. Fabricatore AN, Wadden TA, Moore RH, Butryn ML, Gravallese EA, Erondu NE, et al. Attrition from randomized controlled trials of

pharmacological weight loss agents: a systematic review and analysis. Obes Rev. 2009;10(3):333-41.

213. Uchino K, Billheimer D, Cramer SC. Entry criteria and baseline characteristics predict outcome in acute stroke trials. Stroke.

2001;32(4):909-16.

214. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and

quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. American Journal of Psychiatry. 2006;163(2):185-94.

215. Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical

journals: a systematic sampling review. JAMA. 2007;297:1233-40.

216. Gandhi M, Ameli N, Bacchetti P, Sharp GB, French AL, Young M, et al. Eligibility criteria for HIV clinical trials and generalizability of results:

the gap between published reports and study protocols. AIDS. 2005;19:1885-96.

217. Blumle A, Meerpohl JJ, Rucker G, Antes G, Schumacher M, von EE. Reporting of eligibility criteria of randomised trials: cohort study

comparing trial protocols with subsequent articles. BMJ. 2011;342:d1828.

218. Montori VM, Wang YG, onso-Coello P, Bhagra S. Systematic evaluation of the quality of randomized controlled trials in diabetes. Diabetes

Care. 2006;29(8):1833-8.

219. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A pragmatic–explanatory continuum indicator summary

(PRECIS): a tool to help trial designers. Canadian Medical Association Journal. 2009;180(10):E47-E57.

220.  Jung A, Braun T, Armijo-Olivo S, Challoumas D, Luedtke K. Consensus on the definition and assessment of external validity of randomized

controlled trials: A Delphi study. Res Synth Methods. 2024;15(2):288-302.

221. Tassinari CJ, Higham R, Smith IL, Arnold S, Mujica-Mota R, Metcalfe A, et al. Clinical and cost-effectiveness of Knee Arthroplasty versus Joint

Distraction for Osteoarthritis (KARDS): protocol for a multicentre, phase III, randomised control trial. BMJ Open. 2022;12(6):e062721.

222. Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT Statement for Randomized Trials of Nonpharmacologic Treatments: A

2017 Update and a CONSORT Extension for Nonpharmacologic Trial Abstracts. Ann Intern Med. 2017;167(1):40-7.

223. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic

treatment: explanation and elaboration. Ann Intern Med. 2008;148(4):295-309.

224.  Halm EA, Lee C, Chassin MR. Is volume related to outcome in health care? A systematic review and methodologic critique of the literature.

Ann Intern Med. 2002;137(6):511-20.

225. Devereaux PJ, Bhandari M, Clarke M, Montori VM, Cook DJ, Yusuf S, et al. Need for expertise based randomised controlled trials. BMJ.

2005;330(7482):88.

226. McGrath PD, Wennberg DE, Dickens JD, Jr., Siewers AE, Lucas FL, Malenka DJ, et al. Relation between operator and hospital volume and

outcomes following percutaneous coronary interventions in the era of the coronary stent. Jama. 2000;284(24):3139-44.

227. Oldenburg CE, Pinsky BA, Brogdon J, Chen C, Ruder K, Zhong L, et al. Effect of Oral Azithromycin vs Placebo on COVID-19 Symptoms in

Outpatients With SARS-CoV-2 Infection: A Randomized Clinical Trial. JAMA. 2021;326(6):490-8.

228. Thombs BD, Kwakkenbos L, Carrier ME, Bourgeault A, Tao L, Harb S, et al. Protocol for a partially nested randomised controlled trial to

evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. J Psychosom Res. 2020;135:110132.

229. Prescott M, Lilley-Kelly A, Cundill B, Clarke D, Drake S, Farrin AJ, et al. Home-based Extended Rehabilitation for Older people (HERO): study

protocol for an individually randomised controlled multi-centre trial to determine the clinical and cost-effectiveness of a home-based exercise intervention for older people with frailty as extended rehabilitation following acute illness or injury, including embedded process evaluation. Trials. 2021;22(1):783.

230. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374(9683):86-9.

231. Howick J, Webster RK, Rees JL, Turner R, Macdonald H, Price A, et al. TIDieR-Placebo: A guide and checklist for reporting placebo and sham

controls. PLOS Medicine. 2020;17(9):e1003294.

232. Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard

Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Internal Medicine. 2021;181(12):1612-20.

233. Reis G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, Campos VHS, Ferreira TS, et al. Early Treatment with Pegylated Interferon Lambda

for Covid-19. New England Journal of Medicine. 2023;388(6):518-28.

234. U.S. Food and Drug Administration. CFR - Code of Federal Regulations Title 21, Chapter I, Subchapter D, Part 312: Investigational new drug

application. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312&showFR=1&subpartNode=21:5.0.1.1.3.4 [Accessed 12 Sept 2023].

235. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.

Bmj. 2019;366:l4898.

236. Panel on Handling Missing Data in Clinical Trials, National Research Council. The Prevention and Treatment of Missing Data in Clinical

Trials. Washington D.C.: The National Academies Press; 2010.

237. Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer.

New England Journal of Medicine. 2023;388(8):719-32.

238. Persch AC, Page SJ. Protocol development, treatment fidelity, adherence to treatment, and quality control. Am J Occup Ther.

2013;67(2):146-53.

239. World Health Organization. Adherence to long-term therapies : evidence for action. Geneva: World Health Organization; 2003.

240. Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967;20(8):637-48.

241. Zwarenstein M. 'Pragmatic' and 'explanatory' attitudes to randomised trials. J R Soc Med. 2017;110(5):208-18.

242. Glasziou P, Matthews R, Boutron I, Chalmers I, Armitage P. The differences and overlaps between 'explanatory' and 'pragmatic' controlled

trials: a historical perspective. J R Soc Med. 2023;116(12):425-32.

243. Vrijens B, Urquhart J. Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther.

2014;95(6):617-26.

244. Matsui D. Strategies to measure and improve patient adherence in clinical trials. Pharmaceut Med. 2009;23(5-6):289-97.

245. European Medicines Agency. ICH E3 Structure and Content of Clinical Study Reports (CPMP/ICH/137/95). 1996 Available at:

https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-3-structure-content-clinical-study-reports-step-5_en.pdf [Accessed 12 Sept 2023].

246. Caricchio R, Abbate A, Gordeev I, Meng J, Hsue PY, Neogi T, et al. Effect of Canakinumab vs Placebo on Survival Without Invasive

Mechanical Ventilation in Patients Hospitalized With Severe COVID-19: A Randomized Clinical Trial. JAMA. 2021;326(3):230-9.

247. Sackett DL. Clinician-trialist rounds: 5. Cointervention bias--how to diagnose it in their trial and prevent it in yours. Clin Trials.

2011;8(4):440-2.

248. Wijaya M, Fischer G, Saunderson RB. The efficacy and safety of deucravacitinib compared to methotrexate, in patients with vulvar lichen

planus who have failed topical therapy with potent corticosteroids: a study protocol for a single-centre double-blinded randomised controlled trial. Trials. 2024;25(1):181.

249. Lervik LCN, Vasseljen O, Austad B, Bach K, Bones AF, Granviken F, et al. SupportPrim—a computerized clinical decision support system for

stratified care for patients with musculoskeletal pain complaints in general practice: study protocol for a randomized controlled trial. Trials. 2023;24(1):267.

250. Chan AW, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials:

comparison of protocols to published articles. JAMA. 2004;291(20):2457-65.

251. Chan AW, Krleza-Jeric K, Schmid I, Altman DG. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health

Research. CMAJ Canadian Medical Association Journal. 2004;171(7):735-40.

252.  Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database--update and key issues. N Engl J Med.

2011;364(9):852-60.

253. Saquib N, Saquib J, Ioannidis JPA. Practices and impact of primary outcome adjustment in randomized controlled trials: meta-

epidemiologic study. BMJ : British Medical Journal. 2013;347:f4313.

254. Snapinn S. Some remaining challenges regarding multiple endpoints in clinical trials. Stat Med. 2017;36(28):4441-5.

255. Smyth RM, Kirkham JJ, Jacoby A, Altman DG, Gamble C, Williamson PR. Frequency and reasons for outcome reporting bias in clinical trials:

interviews with trialists. Bmj. 2011;342:c7153.

256. Redmond S, von Elm E, Blümle A, Gengler M, Gsponer T, Egger M. Cohort study of trials submitted to ethics committee identified

discrepant reporting of outcomes in publications. J Clin Epidemiol. 2013;66(12):1367-75.

257. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and

presentation. PLoS Med. 2008;5(11):e217.

258.  Dwan K, Altman DG, Cresswell L, Blundell M, Gamble CL, Williamson PR. Comparison of protocols and registry entries to published

reports for randomised controlled trials. Cochrane Database of Systematic Reviews. 2011;1:MR000031.

259.  van den Bogert CA, Souverein PC, Brekelmans CTM, Janssen SWJ, Koëter GH, Leufkens HGM, et al. Primary endpoint discrepancies were

found in one in ten clinical drug trials. Results of an inception cohort study. Journal of Clinical Epidemiology. 2017;89:199-208.

260. Berendt L, Callréus T, Petersen LG, Bach KF, Poulsen HE, Dalhoff K. From protocol to published report: a study of consistency in the

reporting of academic drug trials. Trials. 2016;17(1):100.

261. Chan AW. Access to clinical trial data. BMJ. 2011;342:d80.

262. Mayo-Wilson E, Fusco N, Li T, Hong H, Canner JK, Dickersin K. Multiple outcomes and analyses in clinical trials create challenges for

interpretation and research synthesis. Journal of Clinical Epidemiology. 2017;86:39-50.

263. Calméjane L, Dechartres A, Tran VT, Ravaud P. Making protocols available with the article improved evaluation of selective outcome

reporting. Journal of Clinical Epidemiology. 2018;104:95-102.

264. Williamson P, Altman D, Blazeby J, Clarke M, Gargon E. Driving up the quality and relevance of research through the use of agreed core

outcomes. J Health Serv Res Policy. 2012;17(1):1-2.

265. Hughes KL, Clarke M, Williamson PR. A systematic review finds Core Outcome Set uptake varies widely across different areas of health. J

Clin Epidemiol. 2021;129:114-23.

266. The COMET Initiative. Accessed at: https://www.comet-initiative.org/ on June 19, 2024.

267. Perlmutter AS, Tran VT, Dechartres A, Ravaud P. Statistical controversies in clinical research: comparison of primary outcomes in protocols,

public clinical-trial registries and publications: the example of oncology trials. Annals of Oncology. 2017;28(4):688-95.

268. Ciani O, Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, et al. A framework for the definition and interpretation of the use of

surrogate endpoints in interventional trials. EClinicalMedicine. 2023;65:102283.

269. Bhandari M, Lochner H, Tornetta P, III. Effect of continuous versus dichotomous outcome variables on study power when sample sizes of

orthopaedic randomized trials are small. Arch Orthop Trauma Surg. 2002;122(2):96-8.

270. Verhagen AP, de Vet HCW, Willemsen S, Stijnen T. A meta-regression analysis shows no impact of design characteristics on outcome in

trials on tension-type headaches. J Clin Epi. 2008;61(8):813-8.

271. Légaré S, Chagnon M, Palijan A, Kojok K, Bissonnette R. Sensitivity of clinician-assessed efficacy outcome measurement instruments in

trials of topical therapies for atopic dermatitis: a systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology. 2022;36(2):196-212.

272. Wang Y, Parpia S, Couban R, Wang Q, Armijo-Olivo S, Bassler D, et al. Compelling evidence from meta-epidemiological studies

demonstrates overestimation of effects in randomized trials that fail to optimize randomization and blind patients and outcome assessors. J Clin Epidemiol. 2024;165:111211.

273. Adigweme I, Akpalu E, Yisa M, Donkor S, Jarju LB, Danso B, et al. Study protocol for a phase 1/2, single-centre, double-blind, double-

dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]. Trials. 2022;23(1):775.

274.  Junqueira DR, Zorzela L, Golder S, Loke Y, Gagnier JJ, Julious SA, et al. CONSORT Harms 2022 statement, explanation, and elaboration:

updated guideline for the reporting of harms in randomised trials. BMJ. 2023;381:e073725.

275. Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851-70.

276. Le-Rademacher J, Hillman SL, Meyers J, Loprinzi CL, Limburg PJ, Mandrekar SJ. Statistical controversies in clinical research: Value of adverse

events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials. Ann Oncol. 2017;28(6):1183-90.

277. Qureshi R, Mayo-Wilson E, Li T. Harms in Systematic Reviews Paper 1: An introduction to research on harms. J Clin Epidemiol.

2022;143:186-96.

278. Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: a randomized,

controlled trial.[erratum appears in Ann Intern Med. 2006 Jul 18;145(2):156]. Annals of Internal Medicine. 2006;144(4):257-61.

279. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed. N Engl J Med. 2006;354(11):1193.

280. Wright JM, Perry TL, Bassett KL, Chambers GK. Reporting of 6-month vs 12-month data in a clinical trial of celecoxib. Jama.

2001;286(19):2398-400.

281. Mayo-Wilson E, Fusco N, Li T, Hong H, Canner JK, Dickersin K, et al. Harms are assessed inconsistently and reported inadequately part 1:

systematic adverse events. J Clin Epidemiol. 2019;113:20-7.

282. Mayo-Wilson E, Fusco N, Li T, Hong H, Canner JK, Dickersin K, et al. Harms are assessed inconsistently and reported inadequately Part 2:

nonsystematic adverse events. J Clin Epidemiol. 2019;113:11-9.

283. Schroll JB, Penninga EI, Gøtzsche PC. Assessment of Adverse Events in Protocols, Clinical Study Reports, and Published Papers of Trials of

Orlistat: A Document Analysis. PLoS Med. 2016;13(8):e1002101.

284. Levit LA, Perez RP, Smith DC, Schilsky RL, Hayes DF, Vose JM. Streamlining Adverse Events Reporting in Oncology: An American Society of

Clinical Oncology Research Statement. J Clin Oncol. 2018;36(6):617-23.

285. Sherman RB, Woodcock J, Norden J, Grandinetti C, Temple RJ. New FDA regulation to improve safety reporting in clinical trials. N Engl J

Med. 2011;365(1):3-5.

286. Daly CD, Lim KZ, Lewis J, Saber K, Molla M, Bar-Zeev N, et al. Lumbar microdiscectomy and post-operative activity restrictions: a protocol

for a single blinded randomised controlled trial. BMC Musculoskeletal Disorders. 2017;18(1):312.

287. Ross S, Grant A, Counsell C, Gillespie W, Russell I, Prescott R. Barriers to participation in randomised controlled trials: a systematic review. J

Clin Epi. 1999;52(12):1143-56.

288. Laursen DRT, Paludan-Müller AS, Hróbjartsson A. Randomized clinical trials with run-in periods: frequency, characteristics and reporting.

Clin Epidemiol. 2019;11:169-84.

289. Dickenson E, Griffin XL, Achten J, Mironov K, O'Connor H, Parsons N, et al. Randomised controlled trial comparing intraoperative cell

salvage and autotransfusion with standard care in the treatment of hip fractures: a protocol for the WHITE 9 study. BMJ Open. 2022;12(6):e062338.

290.  Paton MF, Gierula J, Jamil HA, Lowry JE, Byrom R, Gillott RG, et al. Optimising pacemaker therapy and medical therapy in pacemaker

patients for heart failure: protocol for the OPT-PACE randomised controlled trial. BMJ Open. 2019;9(7):e028613.

291. Cook JA, Hislop J, Altman DG, Fayers P, Briggs AH, Ramsay CR, et al. Specifying the target difference in the primary outcome for a

randomised controlled trial: guidance for researchers. Trials. 2015;16:12.

292.  Cook JA, Julious SA, Sones W, Hampson LV, Hewitt C, Berlin JA, et al. DELTA(2) guidance on choosing the target difference and undertaking

and reporting the sample size calculation for a randomised controlled trial. BMJ. 2018;363:k3750.

293. Cochrane Prospective Meta-Analysis (PMA) Methods Group. Accessed at: https://methods.cochrane.org/pma/ on June 19, 2024.

294. Charles P, Giraudeau B, Dechartres A, Baron G, Ravaud P. Reporting of sample size calculation in randomised controlled trials: review. BMJ.

2009;338:b1732.

295. Dekker J, de Boer M, Ostelo R. Minimal important change and difference in health outcome: An overview of approaches, concepts, and

methods. Osteoarthritis Cartilage. 2024;32(1):8-17.

296. Vickers AJ. Underpowering in randomized trials reporting a sample size calculation. J Clin Epidemiol. 2003;56(8):717-20.

297. Proschan MA. Sample size re-estimation in clinical trials. Biom J. 2009;51(2):348-57.

298. Clark T, Berger U, Mansmann U. Sample size determinations in original research protocols for randomised clinical trials submitted to UK

research ethics committees: review. BMJ : British Medical Journal. 2013;346:f1135.

299.  Julious SA, Campbell MJ, Altman DG. Estimating sample sizes for continuous, binary, and ordinal outcomes in paired comparisons:

practical hints. J Biopharm Stat. 1999;9(2):241-51.

300. Pals SL, Murray DM, Alfano CM, Shadish WR, Hannan PJ, Baker WL. Individually randomized group treatment trials: a critical appraisal of

frequently used design and analytic approaches. Am J Pub Health. 2008;98(8):1418-24.

301.       Eldridge S, Ashby D, Bennett C, Wakelin M, Feder G. Internal and external validity of cluster randomised trials: Systematic review of recent trials. British Medical Journal. 2008;336(7649):876-80.

302.       Eldridge SM, Ashby D, Feder GS, Rudnicka AR, Ukoumunne OC. Lessons for cluster randomized trials in the twenty-first century: a systematic review of trials in primary care. Clin Trials. 2004;1(1):80-90.

303.       Murray DM, Pals SL, Blitstein JL, Alfano CM, Lehman J. Design and analysis of group-randomized trials in cancer: A review of current practices. J Natl Cancer Inst. 2008;100(7):483-91.

304.       Dekkers OM, Cevallos M, Bührer J, Poncet A, Ackermann Rau S, Perneger TV, et al. Comparison of noninferiority margins reported in protocols and publications showed incomplete and inconsistent reporting. J Clin Epidemiol. 2015;68(5):510-7.

305.       Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. BMJ. 2016;355:i5239.

306.       Lewis M, Bromley K, Sutton CJ, McCray G, Myers HL, Lancaster GA. Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back! Pilot and Feasibility Studies. 2021;7(1):40.

307.       Teresi JA, Yu X, Stewart AL, Hays RD. Guidelines for Designing and Evaluating Feasibility Pilot Studies. Med Care. 2022;60(1):95-103.

308.       Pitpitan EV, Horvath KJ, Aldous J, Stockman JK, Patterson TL, Liang M, et al. Peers plus mobile app for treatment in HIV (PATH): protocol for a randomized controlled trial to test a community-based integrated peer support and mHealth intervention to improve viral suppression among Hispanic and Black people living with HIV. Trials. 2024;25(1):212.

309.       Budge J, Carrell T, Yaqub M, Wafa H, Waltham M, Pilecka I, et al. The ARIA trial protocol: a randomised controlled trial to assess the clinical, technical, and cost-effectiveness of a cloud-based, ARtificially Intelligent image fusion system in comparison to standard treatment to guide endovascular Aortic aneurysm repair. Trials. 2024;25(1):214.

310.       Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knights R, et al. Recruitment to randomised trials: Strategies for trial enrolment and participation study. The STEPS study. Health Technol Assess. 2007;11(48):iii-72.

311.       Pich J, Carne X, Arnaiz JA, Gomez B, Trilla A, Rodes J. Role of a research ethics committee in follow-up and publication of results. Lancet. 2003;361(9362):1015-6.

312.       Walters SJ, Bonacho Dos Anjos Henriques-Cadby I, Bortolami O, Flight L, Hind D, Jacques RM, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the United Kingdom Health Technology Assessment Programme. BMJ Open. 2017;7(3):e015276.

313.       Caldwell PH, Hamilton S, Tan A, Craig JC. Strategies for increasing recruitment to randomised controlled trials: systematic review. PLoS Med. 2010;7(11):e1000368.

314.       Treweek S, Pitkethly M, Cook J, Fraser C, Mitchell E, Sullivan F, et al. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018;2(2):Mr000013.

315.       Miller NL, Markowitz JC, Kocsis JH, Leon AC, Brisco ST, Garno JL. Cost effectiveness of screening for clinical trials by research assistants versus senior investigators. Journal of Psychiatric Research. 1999;33(2):81-5.

316.       Tworoger SS, Yasui Y, Ulrich CM, Nakamura H, LaCroix K, Johnston R, et al. Mailing strategies and recruitment into an intervention trial of the exercise effect on breast cancer biomarkers. Cancer Epidemiol Biomarkers Prev. 2002;11(1):73-7.

317.       Schroy P.C. r, Glick JT, Robinson P, Lydotes MA, Heeren TC, Prout M, et al. A cost-effectiveness analysis of subject recruitment strategies in the HIPAA era: results from a colorectal cancer screening adherence trial. Clin Trials. 2009;6(6):597-609.

318.       O'Sullivan Greene E, Shiely F. Recording and reporting of recruitment strategies in trial protocols, registries, and publications was nonexistent. Journal of Clinical Epidemiology. 2022;152:248-56.

319.       Xu B, Lin C, Guo C, Wang H. Comparing conventional treatment, single-target rTMS, or dual-target rTMS for the treatment of post-stroke cognitive impairment — clinical effects and neuroscientific insights: study protocol for a randomized controlled trial. Trials. 2023;24(1):478.

320.       Parker AE, Scull TM, Kennedy KL. Efficacy of DigiKnowItNews: Teen, a multimedia educational website for adolescents about pediatric clinical trials: study protocol for a randomized controlled trial. Trials. 2023;24(1):436.

321.       Peyton D, Wadley G, Hackworth N, Grobler A, Hiscock H. A co-designed website (FindWays) to improve mental health literacy of parents of children with mental health problems: Protocol for a pilot randomised controlled trial. PLOS ONE. 2023;18(3):e0273755.

322.       Schulz KF, Grimes DA. Essential Concepts in Clinical Research: randomized controlled trials and observational epidemiology. 2nd ed. Edinburgh, UK: Elsevier; 2019.

323.       Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized? Trials. 2009;10:46.

324.       Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c869.

325.       Odgaard-Jensen J, Vist GE, Timmer A, Kunz R, Akl EA, Schünemann H, et al. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews. 2011;4:MR000012.

326.       Savović J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med. 2012;157(6):429-38.

327.       Savović J, Jones HE, Altman DG, Harris RJ, Jűni P, Pildal J, et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies. 2012;16:35.

328.       Savović J, Turner RM, Mawdsley D, Jones HE, Beynon R, Higgins JPT, et al. Association Between Risk-of-Bias Assessments and Results of Randomized Trials in Cochrane Reviews: The ROBES Meta-Epidemiologic Study. American Journal of Epidemiology. 2017;187(5):1113-22.

329.       Saltaji H, Armijo-Olivo S, Cummings GG, Amin M, da Costa BR, Flores-Mir C. Impact of Selection Bias on Treatment Effect Size Estimates in Randomized Trials of Oral Health Interventions: A Meta-epidemiological Study. Journal of Dental Research. 2018;97(1):5-13.

330.       Pildal J, Chan AW, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ. 2005;330(7499):1049.

331.       Mhaskar R, Djulbegovic B, Magazin A, Soares HP, Kumar A. Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. J Clin Epidemiol. 2012;65(6):602-9.

332.       Di Stasi S, Chaudhari AMW, Renshaw S, Wei L, Ward L, Arhos EK, et al. ABVENTURE-P pilot trial of physical therapy versus standard of care following ventral hernia repair: Protocol for a randomized controlled trial. PLOS ONE. 2023;18(7):e0289038.

333.       Harvey LA, Dunlop SA, Churilov L, Hsueh YS, Galea MP. Early intensive hand rehabilitation after spinal cord injury ("Hands On"): a protocol for a randomised controlled trial. Trials. 2011;12:14.

334.       McEntegart DJ. The pursuit of balance using stratified and dynamic randomization techniques: an overview. Drug Inf J. 2003;37(3):293-308.

335.       Schulz KF, Grimes DA. Generation of allocation sequences in randomised trials: chance, not choice. Lancet. 2002;359(9305):515-9.

336.       Altman DG, Bland JM. How to randomise. BMJ. 1999;319(7211):703-4.

337.       Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273(5):408-12.

338.       Kernan WN, Viscoli CM, Makuch RW, Brass LM, Horwitz RI. Stratified randomization for clinical trials. J Clin Epidemiol. 1999;52(1):19-26.

339.       Han B, Enas NH, McEntegart D. Randomization by minimization for unbalanced treatment allocation. Stat Med. 2009;28(27):3329-46.

340.       McPherson GC, Campbell MK, Elbourne DR. Investigating the relationship between predictability and imbalance in minimisation: a simulation study. Trials. 2013;14:86.

341.       Altman DG. Practical statistics for medical research. London, UK: Chapman & Hall/CRC; 1991.

342.       Treasure T, MacRae KD. Minimisation: the platinum standard for trials?. Randomisation doesn't guarantee similarity of groups; minimisation does. BMJ. 1998;317(7155):362-3.

343.       Berger VW. Varying the block size does not conceal the allocation. J Crit Care. 2006;21(2):229-30.

344.       Berger VW. Minimization, by its nature, precludes allocation concealment, and invites selection bias. Contemp Clin Trials. 2010;31(5):406.

345.       Martel G, Lenet T, Wherrett C, Carrier F-M, Monette L, Workneh A, et al. Phlebotomy resulting in controlled hypovolemia to prevent blood loss in major hepatic resections (PRICE-2): study protocol for a phase 3 randomized controlled trial. Trials. 2023;24(1):38.

346.       Pereira RA, Virella D, Perdigoto R, Marcelino P, Saliba F, Germano N. Continuous passive paracentesis versus large-volume paracentesis in the prevention and treatment of intra-abdominal hypertension in the critically ill cirrhotic patient with ascites (COPPTRIAHL): study protocol for a randomized controlled trial. Trials. 2023;24(1):534.

347.       Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359(9306):614-8.

348.       Clark L, Schmidt U, Tharmanathan P, Adamson J, Hewitt C, Torgerson D. Allocation concealment: a methodological review. Journal of Evaluation in Clinical Practice. 2013;19(4):708-12.

349.       Clark L, Mitchell N, Hewitt C, Torgerson D. Exploring engagement with authors of randomised controlled trials to develop recommendations to improve allocation concealment implementation and reporting [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research. 2021;10:83.

350.       Herbison P, Hay-Smith J, Gillespie WJ. Different methods of allocation to groups in randomized trials are associated with different levels of bias. A meta-epidemiological study. J Clin Epidemiol. 2011;64(10):1070-5.

351.       Kunz R, Vist G, Oxman AD. Randomisation to protect against selection bias in healthcare trials. Cochrane Database of Systematic Reviews. 2007;2:MR000012.

352.       Ismael S, Vaz C, Durão C, Silvestre MP, Calhau C, Teixeira D, et al. The impact of Hafnia alvei HA4597™ on weight loss and glycaemic control after bariatric surgery — study protocol for a triple-blinded, blocked randomized, 12-month, parallel-group, placebo-controlled clinical trial. Trials. 2023;24(1):362.

353.       Bikic A, Dalsgaard S, Olsen KD, Sukhodolsky DG. Organizational skills training for children with ADHD: study protocol for a randomized, controlled trial. Trials. 2021;22(1):752.

354.       Levin JB, Briggs F, Blixen C, Bauer M, Einstadter D, Albert JM, et al. A randomized controlled trial of customized adherence enhancement (CAE-E): study protocol for a hybrid effectiveness-implementation project. Trials. 2022;23(1):634.

355.       Martini S, Marino F, Magistrelli L, Contaldi E, Cosentino M, Comi C. The PROB-PD trial: a pilot, randomised, placebo-controlled study protocol to evaluate the feasibility and potential efficacy of probiotics in modulating peripheral immunity in subjects with Parkinson’s disease. Pilot and Feasibility Studies. 2023;9(1):77.

356.       Hróbjartsson A, Gøtzsche PC. Placebo treatment for all clinical conditions. Cochrane Database of Systematic Reviews. 2010;1:CD003974.

357.       Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomised clinical trials with binary outcomes: systematic review of trials with both blinded and non-blinded outcome assessors. Bmj. 2012;344:e1119.

358.       Hróbjartsson A, Emanuelsson F, Skou Thomsen AS, Hilden J, Brorson S. Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies. Int J Epidemiol. 2014;43(4):1272-83.

359.       Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ. 2001;323(7303):42-6.

360.       Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis. Int J Epidemiol. 2005;34(1):79-87.

361.       Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Burgi E, Scherer M, et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ. 2009;339:b3244.

362.       Schulz KF, Chalmers I, Altman DG. The landscape and lexicon of blinding in randomized trials. Ann Intern Med. 2002;136(3):254-9.

363.       Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Control Clin Trials. 1996;17(4):285-90.

364.       Grant AM, Altman DG, Babiker AB, Campbell MK, Clemens FJ, Darbyshire JH, et al. Issues in data monitoring and interim analysis of trials. Health Technol Assess. 2005;9(7):1-238.

365.       Boutron I, Estellat C, Guittet L, Dechartres A, Sackett DL, Hróbjartsson A, et al. Methods of blinding in reports of randomized controlled trials assessing pharmacological treatments: a systematic review. PLoS Med. 2006;3:e425.

366.       Boutron I, Guittet L, Estellat C, Moher D, Hróbjartsson A, Ravaud P. Reporting methods of blinding in randomized trials assessing nonpharmacological treatments. PLoS Med. 2007;4(2):e61.

367.       Lieverse R, Nielen MM, Veltman DJ, Uitdehaag BM, van Someren EJ, Smit JH, et al. Bright light in elderly subjects with nonseasonal major depressive disorder: a double blind randomised clinical trial using early morning bright blue light comparing dim red light treatment. Trials. 2008;9:48.

368.       Devereaux PJ, Manns BJ, Ghali WA, Quan H, Lacchetti C, Montori VM, et al. Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials. JAMA. 2001;285(15):2000-3.

369.       Haahr MT, Hróbjartsson A. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors. Clin Trials. 2006;3(4):360-5.

370.       Yu H, Liu M, Zhang X, Ma T, Yang J, Wu Y, et al. The effect of tranexamic acid on intraoperative blood loss in patients undergoing brain meningioma resections: Study protocol for a randomized controlled trial. PLOS ONE. 2023;18(8):e0290725.

371.       Jensen JS, Bielefeldt A, Hróbjartsson A. Active placebo control groups of pharmacological interventions were rarely used but merited serious consideration: a methodological overview. J Clin Epidemiol. 2017;87:35-46.

372.       Laursen DR, Nejstgaard CH, Bjørkedal E, Frost AD, Hansen MR, Paludan-Müller AS, et al. Impact of active placebo controls on estimated drug effects in randomised trials: a systematic review of trials with both active placebo and standard placebo. Cochrane Database Syst Rev. 2023;3(3):Mr000055.

373.       Bello S, Moustgaard H, Hróbjartsson A. Unreported formal assessment of unblinding occurred in 4 of 10 randomized clinical trials, unreported loss of blinding in 1 of 10 trials. Journal of Clinical Epidemiology. 2017;81:42-50.

374.       Fergusson D, Glass KC, Waring D, Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ. 2004;328:432.

375.       Sackett DL. Clinician-trialist rounds: 6. Testing for blindness at the end of your trial is a mug's game. Clin Trials. 2011;8(5):674-6.

376.       Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 changes and testing blindness in RCTs. Lancet. 2010;375(9721):1144-6.

377.       Bello S, Moustgaard H, Hróbjartsson A. The risk of unblinding was infrequently and incompletely reported in 300 randomized clinical trial publications. Journal of Clinical Epidemiology. 2014;67(10):1059-69.

378.       Hrobjartsson A, Boutron I. Blinding in randomized clinical trials: imposed impartiality. Clin Pharmacol Ther. 2011;90(5):732-6.

379.       Liu S, Liu J-T, Chen L, Fan T-Y, Cui X-J, Cheng S-D, et al. Efficacy of five-step shoulder manipulation for rotator cuff-related shoulder pain: protocol for a multicenter randomized controlled trial. Trials. 2023;24(1):498.

380.       Smith LC, Mariegaard L, Vernal DL, Christensen AG, Albert N, Thomas N, et al. The CHALLENGE trial: the effects of a virtual reality-assisted exposure therapy for persistent auditory hallucinations versus supportive counselling in people with psychosis: study protocol for a randomised clinical trial. Trials. 2022;23(1):773.

381.       Truthmann J, Freyer Martins Pereira J, Richter A, Schuster F, Witte A, Böhm S, et al. Prednisolone Versus Colchicine for Acute Gout in Primary Care (COPAGO): protocol for a two-arm multicentre, pragmatic, prospective, randomized, double-blind, controlled clinical trial of prednisolone and colchicine for non-inferiority with a parallel group design. Trials. 2023;24(1):643.

382.       Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624-32.

383.       Cohen SB, Strand V, Aguilar D, Ofman JJ. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. Rheumatology (Oxford). 2004;43(6):704-11.

384.       Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM. How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol. 2004;22(17):3485-90.

385.       Bent S, Padula A, Avins AL. Brief communication: Better ways to question patients about adverse medical events: a randomized, controlled trial. Ann Intern Med. 2006;144(4):257-61.

386.       Rorie DA, Flynn RWV, Grieve K, Doney A, Mackenzie I, MacDonald TM, et al. Electronic case report forms and electronic data capture within clinical trials and pharmacoepidemiology. British Journal of Clinical Pharmacology. 2017;83(9):1880-95.

387.       Kryworuchko J, Stacey D, Bennett C, Graham ID. Appraisal of primary outcome measures used in trials of patient decision support. Patient Educ Couns. 2008;73(3):497-503.

388.       Calvert M, King M, Mercieca-Bebber R, Aiyegbusi O, Kyte D, Slade A, et al. SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials. BMJ Open. 2021;11(6):e045105.

389.       Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry. 2000;176:249-52.

390.       Mc Cord KA, Ewald H, Agarwal A, Glinz D, Aghlmandi S, Ioannidis JPA, et al. Treatment effects in randomised trials using routinely collected data for outcome assessment versus traditional trials: meta-research study. BMJ. 2021;372:n450.

391.       Williams GW. The other side of clinical trial monitoring; assuring data quality and procedural adherence. Clin Trials. 2006;3(6):530-7.

392.       Kyte D, Duffy H, Fletcher B, Gheorghe A, Mercieca-Bebber R, King M, et al. Systematic Evaluation of the Patient-Reported Outcome (PRO) Content of Clinical Trial Protocols. PLOS ONE. 2014;9(10):e110229.

393.       Logan B, Viecelli AK, Johnson DW, Aquino EM, Bailey J, Comans TA, et al. Study protocol for The GOAL Trial: comprehensive geriatric assessment for frail older people with chronic kidney disease to increase attainment of patient-identified goals—a cluster randomised controlled trial. Trials. 2023;24(1):365.

394.       Hotopf M, Lewis G, Normand C. Putting trials on trial--the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health. 1997;51:354-8.

395.       Heo M, Papademetriou E, Meyers BS. Design characteristics that influence attrition in geriatric antidepressant trials: meta-analysis. Int J Geriatr Psychiatry. 2009;24(9):990-1001.

396.       Gillies K, Kearney A, Keenan C, Treweek S, Hudson J, Brueton VC, et al. Strategies to improve retention in randomised trials. Cochrane Database of Systematic Reviews. 2021(3).

397.       PRincipleS for handling end-of-participation EVEnts in clinical trials REsearch: the PeRSEVERE principles. Available at: https://persevereprinciples.org/the-persevere-principles/

[Accessed 08 Nov 2023].

398.       Fleming TR. Addressing missing data in clinical trials. Ann Intern Med. 2011;154(2):113-7.

399.       Liu M, Wei L, Zhang J. Review of guidelines and literature for handling missing data in longitudinal clinical trials with a case study. Pharm Stat. 2006;5(1):7-18.

400.       Sih C, Protopopoff N, Koffi AA, Ahoua Alou LP, Dangbenon E, Messenger LA, et al. Efficacy of chlorfenapyr-pyrethroid and piperonyl butoxide-pyrethroid long-lasting insecticidal nets (LLINs) compared to pyrethroid-only LLINs for malaria control in Côte d’Ivoire: a three group, cluster randomised trial. Trials. 2024;25(1):151.

401.       Lebedys E, Famatiga-Fay C, Bhatkar P, Johnson D, Viswanathan G, Zozus MN. Data Management Plan. Journal of the Society for Clinical Data Management. 2021;1(4).

402.       NIH. Data management and sharing policy. Available at: https://sharing.nih.gov/data-management-and-sharing-policy/data-management#:~:text=NIH%20encourages%20data%20management%20and,repurposing%20datasets%20for%20secondary%20research. [Accessed 29 Jan 2024]. 2023.

403.       Williams M, Bagwell J, Nahm Zozus M. Data management plans: the missing perspective. Journal of Biomedical Informatics. 2017;71:130-42.

404.       Walther B, Hossin S, Townend J, Abernethy N, Parker D, Jeffries D. Comparison of electronic data capture (EDC) with the standard data capture method for clinical trial data. PLoS One. 2011;6(9):e25348.

405.       Fong DYT. Data management and quality assurance. Drug Inf J. 2001;35(3):839-44.

406.       Kawado M, Hinotsu S, Matsuyama Y, Yamaguchi T, Hashimoto S, Ohashi Y. A comparison of error detection rates between the reading aloud method and the double data entry method. Control Clin Trials. 2003;24(5):560-9.

407.       Edwards MR, Forbes G, Walker N, Morton DG, Mythen MG, Murray D, et al. Fluid Optimisation in Emergency Laparotomy (FLO-ELA) Trial: study protocol for a multi-centre randomised trial of cardiac output-guided fluid therapy compared to usual care in patients undergoing major emergency gastrointestinal surgery. Trials. 2023;24(1):313.

408.       Zoungas S, Curtis A, Spark S, Wolfe R, McNeil JJ, Beilin L, et al. Statins for extension of disability-free survival and primary prevention of cardiovascular events among older people: protocol for a randomised controlled trial in primary care (STAREE trial). BMJ Open. 2023;13(4):e069915.

409.       Kahan BC, Jairath V, Doré CJ, Morris TP. The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies. Trials. 2014;15(1):139.

410.       Morris TP, Walker AS, Williamson EJ, White IR. Planning a method for covariate adjustment in individually randomised trials: a practical guide. Trials. 2022;23(1):328.

411.       Hernández AV, Eijkemans MJ, Steyerberg EW. Randomized controlled trials with time-to-event outcomes: how much does prespecified covariate adjustment increase power? Ann Epidemiol. 2006;16(1):41-8.

412.       Li G, Taljaard M, Van den Heuvel ER, Levine MA, Cook DJ, Wells GA, et al. An introduction to multiplicity issues in clinical trials: the what, why, when and how. International Journal of Epidemiology. 2016;46(2):746-55.

413.       Dmitrienko A, D’Agostino RB. Multiplicity Considerations in Clinical Trials. New England Journal of Medicine. 2018;378(22):2115-22.

414.       Cornelius VR, Phillips R. Improving the analysis of adverse event data in randomized controlled trials. J Clin Epidemiol. 2022;144:185-92.

415.       Seidler AL, Hunter KE, Cheyne S, Ghersi D, Berlin JA, Askie L. A guide to prospective meta-analysis. BMJ. 2019;367:l5342.

416.       Sullivan TR, Morris TP, Kahan BC, Cuthbert AR, Yelland LN. Categorisation of continuous covariates for stratified randomisation: How should we adjust? Stat Med [Internet]. 2024 Mar 15. Available from: https://www.ncbi.nlm.nih.gov/pubmed/38487976.

417.       Bray R, Hartley A, Wenkert D, Muehlemann N, Natanegara F, Harrell FE, Jr., et al. Why are There not More Bayesian Clinical Trials? Ability to Interpret Bayesian and Conventional Statistics Among Medical Researchers. Ther Innov Regul Sci. 2023;57(3):426-35.

418.       Fors M, González P. Current status of Bayesian clinical trials for oncology, 2020. Contemp Clin Trials Commun. 2020;20:100658.

419.       Abouhajar A, Alcock L, Bigirumurame T, Bradley P, Brown L, Campbell I, et al. Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy. Trials. 2022;23(1):789.

420.       Chalmers I, Matthews R, Glasziou P, Boutron I, Armitage P. Trial analysis by treatment allocated or by treatment received? Origins of 'the intention-to-treat principle' to reduce allocation bias: Part 1. J R Soc Med. 2023;116(10):343-50.

421.       Chalmers I, Matthews R, Glasziou P, Boutron I, Armitage P. Trial analysis by treatment allocated or by treatment received? Origins of 'the intention-to-treat principle' to reduce allocation bias: Part 2. J R Soc Med. 2023;116(11):386-94.

422.       Alshurafa M, Briel M, Akl EA, Haines T, Moayyedi P, Gentles SJ, et al. Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One. 2012;7(11):e49163.

423.       Bell ML, Fiero M, Horton NJ, Hsu C-H. Handling missing data in RCTs; a review of the top medical journals. BMC Medical Research Methodology. 2014;14(1):118.

424.       Yang F, Wittes J, Pitt B. Beware of on-treatment safety analyses. Clin Trials. 2019;16(1):63-70.

425.       Abraha I, Cherubini A, Cozzolino F, Florio RD, Luchetta ML, Rimland JM, et al. Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study. BMJ : British Medical Journal. 2015;350:h2445.

426.       Mohanty S, Holler E, Ortiz D, Meagher A, Perkins A, Bylund P, et al. Delirium and neuropsychological recovery among emergency general surgery survivors (DANE): study protocol for a randomized controlled trial and collaborative care intervention. Trials. 2023;24(1):634.

427.       Akl EA, Briel M, You JJ, Sun X, Johnston BC, Busse JW, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. Bmj. 2012;344:e2809.

428.       Akl EA, Shawwa K, Kahale LA, Agoritsas T, Brignardello-Petersen R, Busse JW, et al. Reporting missing participant data in randomised trials: systematic survey of the methodological literature and a proposed guide. BMJ Open. 2015;5(12):e008431.

429.       Jakobsen JC, Gluud C, Wetterslev J, Winkel P. When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts. BMC Medical Research Methodology. 2017;17(1):162.

430.       Heymans MW, Twisk JWR. Handling missing data in clinical research. Journal of Clinical Epidemiology. 2022;151:185-8.

431.       Bhaskaran K, Smeeth L. What is the difference between missing completely at random and missing at random? Int J Epidemiol. 2014;43(4):1336-9.

432.       White IR, Horton NJ, Carpenter J, medical ri, statistics s, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ. 2011;342:d40.

433.       Austin PC, White IR, Lee DS, van Buuren S. Missing Data in Clinical Research: A Tutorial on Multiple Imputation. Canadian Journal of Cardiology. 2021;37(9):1322-31.

434.       Lachin JM. Fallacies of last observation carried forward analyses. Clin Trials. 2016;13(2):161-8.

435.       Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393.

436.       Hussain JA, White IR, Johnson MJ, Byrne A, Preston NJ, Haines A, et al. Development of guidelines to reduce, handle and report missing data in palliative care trials: A multi-stakeholder modified nominal group technique. Palliat Med. 2022;36(1):59-70.

437.       Armstrong-Buisseret L, Brittain C, David M, Dean G, Griffiths F, Hepburn T, et al. Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis. Trials. 2019;20(1):648.

438.       Dinu M, Lotti S, Pagliai G, Napoletano A, Asensi MT, Giangrandi I, et al. Effects of a chronotype-adapted diet on weight loss, cardiometabolic health, and gut microbiota: study protocol for a randomized controlled trial. Trials. 2024;25(1):152.

439.       Brankovic M, Kardys I, Steyerberg EW, Lemeshow S, Markovic M, Rizopoulos D, et al. Understanding of interaction (subgroup) analysis in clinical trials. Eur J Clin Invest. 2019;49(8):e13145.

440.       Taji Heravi A, Gryaznov D, Schandelmaier S, Kasenda B, Briel M, Group AtSRS. Evaluation of Planned Subgroup Analysis in Protocols of Randomized Clinical Trials. JAMA Network Open. 2021;4(10):e2131503-e.

441.       Fan J, Song F, Bachmann MO. Justification and reporting of subgroup analyses were lacking or inadequate in randomized controlled trials. J Clin Epidemiol. 2019;108:17-25.

442.       Desai M, Pieper KS, Mahaffey K. Challenges and solutions to pre- and post-randomization subgroup analyses. Curr Cardiol Rep. 2014;16(10):531.

443.       Hirji KF, Fagerland MW. Outcome based subgroup analysis: a neglected concern. Trials. 2009;10:33.

444.       Wallach JD, Sullivan PG, Trepanowski JF, Sainani KL, Steyerberg EW, Ioannidis JP. Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials. JAMA Intern Med. 2017;177(4):554-60.

445.       Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117.

446.       Morris TP, Kahan BC, White IR. Choosing sensitivity analyses for randomised trials: principles. BMC Medical Research Methodology. 2014;14(1):11.

447.       Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol. 2013;13:92.

448.       Parpia S, Morris TP, Phillips MR, Wykoff CC, Steel DH, Thabane L, et al. Sensitivity analysis in clinical trials: three criteria for a valid sensitivity analysis. Eye. 2022;36(11):2073-4.

449.       Jensen ASR, Valentin JB, Mulvad MG, Hagenau V, Skaarup SH, Johnsen SP, et al. Standard vs. targeted oxygen therapy prehospitally for chronic obstructive pulmonary disease (STOP-COPD): study protocol for a randomised controlled trial. Trials. 2024;25(1):85.

450.       Munch MW, Granholm A, Myatra SN, Vijayaraghavan B, Cronhjort M, Wahlin RR, et al. Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan. Acta Anaesthesiol Scand. 2021;65(6):834-45.

451.       Sydes MR, Altman DG, Babiker AB, Parmar MK, Spiegelhalter DJ, DAMOCLES Group. Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study. Clin Trials. 2004;1(1):48-59.

452.       Ellenberg SS. Independent data monitoring committees: rationale, operations and controversies. Stat Med. 2001;20(17-18):2573-83.

453.       Calis KA, Archdeacon P, Bain R, DeMets D, Donohue M, Elzarrad MK, et al. Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative. Clinical Trials. 2017;14(4):342-8.

454.       Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. Jama. 2012;307(17):1838-47.

455.       Stegert M, Kasenda B, von Elm E, You JJ, Blümle A, Tomonaga Y, et al. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules. Journal of Clinical Epidemiology. 2016;69:152-60.

456.       Ellenberg SS, Fleming TR, DeMets DL. Data monitoring committees in clinical trials: a practical perspective. 2nd ed: Wiley; 2019.

457.       Ochomo EO, Gimnig JE, Bhattarai A, Samuels AM, Kariuki S, Okello G, et al. Evaluation of the protective efficacy of a spatial repellent to reduce malaria incidence in children in western Kenya compared to placebo: study protocol for a cluster-randomized double-blinded control trial (the AEGIS program). Trials. 2022;23(1):260.

458.       Ciolino JD, Kaizer AM, Bonner LB. Guidance on interim analysis methods in clinical trials. J Clin Transl Sci. 2023;7(1):e124.

459.       DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. Lancet. 1999;354(9194):1983-8.

460.       Martens MJ, Logan BR. Statistical rules for safety monitoring in clinical trials. Clin Trials. 2024;21(2):152-61.

461.       Kairalla JA, Coffey CS, Thomann MA, Muller KE. Adaptive trial designs: a review of barriers and opportunities. Trials. 2012;13:145.

462.       Floriani I, Rotmensz N, Albertazzi E, Torri V, De Rosa M, Tomino C, et al. Approaches to interim analysis of cancer randomised clinical trials with time to event endpoints: a survey from the Italian National Monitoring Centre for Clinical Trials. Trials. 2008;9:46.

463.       Renz BW, Adrion C, Klinger C, Ilmer M, D’Haese JG, Buhr H-J, et al. Pylorus resection versus pylorus preservation in pancreatoduodenectomy (PyloResPres): study protocol and statistical analysis plan for a German multicentre, single-blind, surgical, registry-based randomised controlled trial. BMJ Open. 2021;11(11):e056191.

464.       Ker K, Roberts I, Chaudhri R, Fawole B, Beaumont D, Balogun E, et al. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial. Trials. 2018;19(1):712.

465.       TransCelerate Biopharma Inc. Risk-based monitoring. Available at: https://www.transceleratebiopharmainc.com/initiatives/risk-based-monitoring/ [Accessed 06 Dec 2023].

466.       UKCRC Registered CTU Network. Monitoring of clinical trials: a handbook v1.0. 2021 Available at: https://ukcrc-ctu.org.uk/download/6577/?tmstv=1696335948 [Accessed 12 Dec 2023].

467.       Love SB, Yorke-Edwards V, Ward E, Haydock R, Keen K, Biggs K, et al. What is the purpose of clinical trial monitoring? Trials. 2022;23(1):836.

468.       Hsieh S-F, Yorke-Edwards V, Murray ML, Diaz-Montana C, Love SB, Sydes MR. Lack of transparent reporting of trial monitoring approaches in randomised controlled trials: A systematic review of contemporary protocol papers. Clinical Trials. 2023;20(2):121-32.

469.       Daly B, Brawley OW, Gospodarowicz MK, Olopade OI, Fashoyin-Aje L, Smart VW, et al. Remote Monitoring and Data Collection for Decentralized Clinical Trials. JAMA Netw Open. 2024;7(4):e246228.

470.       de Viron S, Trotta L, Steijn W, Young S, Buyse M. Does Central Statistical Monitoring Improve Data Quality? An Analysis of 1,111 Sites in 159 Clinical Trials. Ther Innov Regul Sci. 2024;58(3):483-94.

471.       Klatte K, Pauli-Magnus C, Love SB, Sydes MR, Benkert P, Bruni N, et al. Monitoring strategies for clinical intervention studies. Cochrane Database of Systematic Reviews. 2021(12).

472.       World Medical Association. WMA Declaration of Helsinki - ethical principles for medical research involving human subjects. 2022 Available at https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ [Accessed 15 Nov 2023].

473.       Bessat C, Bingisser R, Schwendinger M, Bulaty T, Fournier Y, Della Santa V, et al. PLUS-IS-LESS project: Procalcitonin and Lung UltraSonography-based antibiotherapy in patients with Lower rESpiratory tract infection in Swiss Emergency Departments: study protocol for a pragmatic stepped-wedge cluster-randomized trial. Trials. 2024;25(1):86.

474.       Wise P, Drury M. Pharmaceutical trials in general practice: the first 100 protocols. An audit by the clinical research ethics committee of the Royal College of General Practitioners. BMJ. 1996;313(7067):1245-8.

475.       Getz KA, Zuckerman R, Cropp AB, Hindle AL, Krauss R, Kaitin KI. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Inf J. 2011;45(3):265-75.

476.       Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med. 2008;358(3):252-60.

477.       Shapiro SH, Weijer C, Freedman B. Reporting the study populations of clinical trials. Clear transmission or static on the line? J Clin Epi. 2000;53(10):973-9.

478.       Chappell L, Alfirevich Z, Chien P, Jarvis S, Thornton JG. A comparison of the published version of randomized controlled trials in a specialist clinical journal with the original trial protocols [abstract]. International Congress on Peer Review and Biomedical Publication; 2005 Sept 16 18; Chicago, Illinois, USA. 2005:27.

479.       Yazici Y, Adler NM, Yazici H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations. Rheumatol. 2008;47(7):1054-7.

480.       Copay AG, Subach BR, Glassman SD, Polly DW, Jr., Schuler TC. Understanding the minimum clinically important difference: a review of concepts and methods. Spine J. 2007;7(5):541-6.

481.       Al-Marzouki S, Roberts I, Evans S, Marshall T. Selective reporting in clinical trials: analysis of trial protocols accepted by the Lancet. Lancet. 2008;372(9634):201.

482.       Losch C, Neuhauser M. The statistical analysis of a clinical trial when a protocol amendment changed the inclusion criteria. BMC Med Res Methodol. 2008;8:16.

483.       U.S. Food and Drug Administration. Code of Federal Regulations, Title 21, Volume 5, 21CFR312.30.  2011. .

484.       European Commission. Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1) (2010/C 82/01). Official Journal of the European Union. 2010.

485.       Waldron C-A, Thomas-Jones E, Cannings-John R, Hood K, Powell C, Roberts A, et al. Oral steroids for the resolution of otitis media with effusion (OME) in children (OSTRICH): study protocol for a randomised controlled trial. Trials. 2016;17(1):115.

486.       López-Parra M, Gil-Rey D, López-González E, González-Rodríguez EM, Simó-Sánchez I, Zamora-Carmona F, et al. Open-label randomized controlled trial to compare wound dressings for patients undergoing hip and knee arthroplasty: study protocol for a randomized controlled trial. Trials. 2018;19(1):357.

487.       Foy R, Parry J, Duggan A, Delaney B, Wilson S, Lewin-Van Den Broek NT, et al. How evidence based are recruitment strategies to randomized controlled trials in primary care? Experience from seven studies. Fam Prac. 2003;20(1):83-92.

488.       Fayter D, McDaid C, Ritchie G, Stirk L, Eastwood A. Systematic review of barriers, modifiers and benefits involved in participation in cancer trials. Centre for Reviews and Dissemination report 31. York, UK.  University of York; 2006. Report No.: 31.

489.       Abraham NS, Young JM, Solomon MJ. A systematic review of reasons for nonentry of eligible patients into surgical randomized controlled trials. Surgery. 2006;139(4):469-83.

490.       Synnot A, Ryan R, Prictor M, Fetherstonhaugh D, Parker B. Audio‐visual presentation of information for informed consent for participation in clinical trials. Cochrane Database of Systematic Reviews. 2014(5).

491.       Wendler D. Assent in paediatric research: theoretical and practical considerations. J Med Ethic. 2006;32:229.

492.       Shepherd V, Wood F, Griffith R, Sheehan M, Hood K. Development of a decision support intervention for family members of adults who lack capacity to consent to trials. BMC Med Inform Decis Mak. 2021;21(1):30.

493.       McRae AD, Weijer C, Binik A, Grimshaw JM, Boruch R, Brehaut JC, et al. When is informed consent required in cluster randomized trials in health research? Trials. 2011;12(1):202.

494.       Denholm JT, Venkatesh B, Davis J, Bowen AC, Hammond NE, Jha V, et al. ASCOT ADAPT study of COVID-19 therapeutics in hospitalised patients: an international multicentre adaptive platform trial. Trials. 2022;23(1):1014.

495.       Beskow LM, Friedman JY, Hardy NC, Lin L, Weinfurt KP. Developing a simplified consent form for biobanking. PLoS One. 2010;5(10):e13302.

496.       Strech D, Bein S, Brumhard M, Eisenmenger W, Glinicke C, Herbst T, et al. A template for broad consent in biobank research. Results and explanation of an evidence and consensus-based development process. European Journal of Medical Genetics. 2016;59(6):295-309.

497.       Pittet LF, Messina NL, Orsini F, Moore CL, Abruzzo V, Barry S, et al. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. New England Journal of Medicine. 2023;388(17):1582-96.

498.       UpGuard. Clinical Trials: How Personal Information for Thousands of Australians was Exposed. 2019 Available at: www.upguard.com/breaches/data-leak-neoclinical-australia-new-zealand [Accessed 12 Nov 2023].

499.       Kalkman S, Mostert M, Gerlinger C, van Delden JJM, van Thiel GJMW. Responsible data sharing in international health research: a systematic review of principles and norms. BMC Medical Ethics. 2019;20(1):21.

500.       Tucker K, Branson J, Dilleen M, Hollis S, Loughlin P, Nixon MJ, et al. Protecting patient privacy when sharing patient-level data from clinical trials. BMC Medical Research Methodology. 2016;16(1):77.

501.       Geetha Sindhuja B, N. C. Protocol for a prospective comparative randomized clinical study for the comparison of two different doses of dexmedetomidine with bupivacaine in pediatric caudal anesthesia for infraumbilical surgeries in a tertiary hospital in central India [version 1; peer review: awaiting peer review]. F1000Research, 13:118 (https://doi.org/10.12688/f1000research.144139.1). 2024.

502.       Richardson HS, Belsky L. The ancillary-care responsibilities of medical researchers. Hastings Center Report. 2004;1:25-33.

503.       Cho HL, Danis M, Grady C. The ethics of uninsured participants accessing healthcare in biomedical research: A literature review. Clin Trials. 2018;15(5):509-21.

504.       Manock SR, Mtoro A, Urbano Nsue Ndong V, Olotu A, Chemba M, Sama Roca AE, et al. Providing Ancillary Care in Clinical Research: A Case of Diffuse Large B-Cell Lymphoma during a Malaria Vaccine Trial in Equatorial Guinea. The American Journal of Tropical Medicine and Hygiene. 2021;104(2):695-9.

505.       Porcino AJ, Shamseer L, Chan AW, Kravitz RL, Orkin A, Punja S, et al. SPIRIT extension and elaboration for n-of-1 trials: SPENT 2019 checklist. Bmj. 2020;368:m122.

506.       Yap C, Rekowski J, Ursino M, Solovyeva O, Patel D, Dimairo M, et al. Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance. BMJ. 2023;383:e076386.

507.       Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, et al. Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration. BMJ. 2024;386:e078525.

508.       Kendall TJ, Robinson M, Brierley DJ, Lim SJ, O'Connor DJ, Shaaban AM, et al. Guidelines for cellular and molecular pathology content in clinical trial protocols: the SPIRIT-Path extension. Lancet Oncol. 2021;22(10):e435-e45.

509.       Dai L, Cheng CW, Tian R, Zhong LL, Li YP, Lyu AP, et al. Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2019;25(1):71-9.

510.       Page MJ, Moher D, Brennan S, McKenzie JE. The PRISMATIC project: protocol for a research programme on novel methods to improve reporting and peer review of systematic reviews of health evidence. Systematic Reviews. 2023;12(1):196.

Reference 1
Reference25
Reference 2
Reference 3
Reference 4
Reference 5
Reference 6
Reference 7
Reference 8
Reference 10
Reference 9
Reference 11
Reference 12
Reference 13
Reference 14
Reference 15
Reference 16
Reference 17
Reference 18
Reference 19
Reference 20
Reference 21
Reference 22
Reference 23
Reference 24
Reference 26
Reference 27
Reference 28
Reference 29
Reference 30
Reference 31
Reference 32
Reference 33
Reference 34
Reference 35
Reference 36
Reference 37
Reference 38
Reference 39
Reference 40
Reference 41
Reference 42
Ref 43
Ref 44
Ref 45
Ref 46
Ref 47
Ref 48
Ref 49
Ref 50
Ref 51
Ref 52
Ref 53
Ref 54
Ref 55
Ref 56
Ref 57
Ref 58
Ref 59
Ref 60
Ref 61
Ref 62
Ref 63
Ref 64
Ref 65
Ref 66
Ref 67
Ref 68
Ref 69
Ref 70
Ref 71
Ref 72
Ref 73
Ref 74
Ref 75
Ref 76
Ref 77
Ref 78
Ref 79
Ref 80
Ref 81
Ref 82
Ref 83
Ref 84
Ref 85
Ref 86
Ref 87
Ref 88
Ref 89
Ref 90
Ref 91
Ref 92
Ref 93
Ref 94
Ref 95
Ref 96
Ref 97
Ref 98
Ref 99
Ref 100
Ref 101
Ref 102
Ref 103
Ref 104
Ref 105
Ref 106
Ref 107
Ref 108
Ref 109
Ref 110
Ref 111
Ref 112
Ref 113
Ref 114
Ref 115
Ref 116
Ref 117
Ref 118
Ref 119
Ref 120
Ref 121
Ref 122
Ref 123
Ref 124
Ref 125
Ref 126
Ref 127
Ref 128
Ref 129
Ref 130
Ref 131
Ref 132
Ref 133
Ref 134
Ref 135
Ref 136
Ref 137
Ref 138
Ref 139
Ref 140
Ref 141
Ref 142
Ref 143
Ref 144
Ref 145
Ref 146
Ref 147
Ref 149
Ref 148
Ref 150
Ref 151
Ref 152
Ref 153
Ref 154
Ref 155
Ref 156
Ref 157
Ref 158
Ref 159
Ref 160
Ref 161
Ref 162
Ref 163
Ref 164
Ref 165
Ref 166
Ref 167
Ref 168
Ref 169
Ref 170
Ref 171
Ref 172
Ref 173
Ref 174
Ref 175
Ref 176
Ref 177
Ref 178
Ref 179
Ref 180
Ref 181
Ref 182
Ref 183
Ref 184
Ref 185
Ref 187
Ref 188
Ref 189
Ref 190
Ref 191
Ref 192
Ref 193
Ref 194
Ref 195
Ref 196
Ref 197
Ref 198
Ref 199
Ref 200
Ref 201
Ref 202
Ref 203
Ref 204
Ref 205
Ref 206
Ref 207
Ref 208
Ref 209
Ref 210
Ref 211
Ref 212
Ref 213
Ref 214
Ref 215
Ref 216
Ref 217
Ref 218
Ref 219
Ref 220
Ref 221
Ref 222
Ref 223
Ref 224
Ref 225
Ref 226
Ref 227
Ref 228
Ref 229
Ref 230
Ref 231
Ref 232
Ref 233
Ref 234
Ref 235
Ref 236
Ref 237
Ref 238
Ref 239
Ref 240
Ref 241
Ref 242
Ref 243
Ref 244
Ref 245
Ref 246
Ref 247
Ref 248
Ref 249
Ref 250
Ref 251
Ref 252
Ref 253
Ref 254
Ref 255
Ref 256
Ref 257
Ref 258
Ref 259
Ref 260
Ref 261
Ref 262
Ref 263
Ref 264
Ref 265
Ref 266
Ref 267
Ref 268
Ref 269
Ref 270
Ref 271
Ref 272
Ref 273
Ref 274
Ref 275
Ref 276
Ref 277
Ref 278
Ref 279
Ref 280
Ref 281
Ref 282
Ref 283
Ref 284
Ref 285
Ref 286
Ref 287
Ref 288
Ref 289
Ref 290
Ref 291
Ref 292
Ref 293
Ref 294
Ref 295
Ref 296
Ref 297
Ref 298
Ref 299
Ref 300
Ref 301
Rf 302
Rf 303
Rf 304
Ref 305
Ref 306
Ref 307
Ref 308
Ref 309
Ref 310
Ref 311
Ref 312
Ref 313
Ref 314
Ref 315
Ref 316
Ref 317
Ref 318
Ref 319
Ref 320
Ref 321
Ref 322
Ref 323
Ref 324
Ref 325
Ref 326
Ref 327
Ref 328
Ref 329
Ref 330
Ref 331
Ref 332
Ref 333
Rf 334
Ref 335
Ref 336
Ref 337
Ref 338
Ref 339
Ref 340
Ref 341
Ref 342
Ref 343
Ref 344
Ref 345
Ref 346
Ref 347
Ref 348
Ref 349
Ref 350
Ref 351
Ref 352
Rf 353
Ref 354
Ref 355
Ref 356
Ref 357
Ref 358
Ref 359
Ref 360
Ref 361
Ref 362
Ref 363
Ref 364
Ref 365
Ref 366
Ref 367
Ref 368
Ref 369
Ref 370
Ref 371
Ref 372
Ref 373
Ref 374
Ref 375
Ref 376
Ref 377
Ref 378
Ref 379
Ref 380
Ref 381
Ref 382
Ref 383
Ref 384
Ref 385
Ref 386
Ref 387
Ref 388
Ref 389
Ref 390
Ref 391
Ref 392
Ref 393
Ref 394
Ref 395
Ref 396
Ref 397
Ref 398
Ref 399
Ref 400
Ref 401
Ref 402
Ref 403
Ref 404
Ref 405
Ref 406
Ref 407
Ref 408
Ref 409
Ref 410
Ref 411
Ref 412
Ref 413
Ref 414
Ref 415
Ref 416
Ref 417
Ref 418
Ref 419
Ref 420
Ref 421
Ref 422
Ref 423
Ref 424
Ref 425
Ref 426
Ref 427
Ref 428
Ref 429
Ref 430
Ref 431
Ref 432
Ref 433
Ref 434
Ref 435
Ref 436
Ref 437
Ref 438
Ref 439
Ref 440
Ref 441
Ref 442
Ref 443
Ref 444
Ref 445
Ref 446
Ref 447
Ref 448
Ref 449
Ref 450
Ref 451
Ref 452
Ref 453
Ref 454
Ref 455
Ref 456
Ref 457
Ref 458
Ref 459
Ref 460
Ref 461
Ref 462
Ref 463
Ref 464
Ref 465
Ref 466
Ref 467
Ref 468
Ref 469
Ref 470
Ref 471
Ref 472
Ref 473
Ref 474
Ref 475
Ref 476
Ref 477
Ref 478
Ref 479
Ref 480
Ref 481
Ref 482
Ref 483
Ref 484
Ref 485
Ref 486
Ref 487
Ref 488
Ref 489
Ref 490
Ref 491
Ref 492
Ref 493
Ref 494
Ref 495
Ref 496
Ref 497
Ref 498
Ref 499
Ref 500
Ref 501
Ref 502
Ref 503
Ref 504
Ref 505
Ref 506
Ref 507
Ref 508
Ref 509
Ref 510
Logo: jointly funded by the UKRI Medical Research Council and the NIHR (National Institute for Health and Care Research)
University of Oxford logo
University of Toronto logo
The University of North Carolina at Chapel Hill logo
University of Southern Denmark (SDU) logo
University of Ottawa (uOttawa) logo
Université Paris Cité (UPC) logo

The 2025 update of SPIRIT and CONSORT, and this website, are funded by the MRC-NIHR: Better Methods, Better Research [MR/W020483/1]. The views expressed are those of the authors and not necessarily those of the NIHR, the MRC, or the Department of Health and Social Care.

Accessibility |  Terms of use  |  Privacy  |  Site map

bottom of page